University of California San Francisco

Publications

  1. Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.
    Huilgol YS, Keane H, Shieh Y, Hiatt RA, Tice JA, Madlensky L, Sabacan L, Fiscalini AS, Ziv E, Acerbi I, Che M, Anton-Culver H, Borowsky AD, Hunt S, Naeim A, Parker BA, van 't Veer LJ, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ
    NPJ Breast Cancer. 2021 Aug 03; 7(1):102.; 
    PubMed
  2. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
    Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ
    NPJ Breast Cancer. 2021 May 25; 7(1):59.; 
    PubMed
  3. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
    Hansen KS, Ghersin H, Piper M, Tavakol M, Lee B, Esserman LJ, Roberts JP, Freise C, Ascher NL, Mukhtar RA
    Am J Transplant. 2021 09; 21(9):3014-3020.; 
    PubMed
  4. Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
    Nachmanson D, Steward J, Yao H, Officer A, Jeong E, O'Keefe TJ, Hasteh F, Jepsen K, Hirst GL, Esserman LJ, Borowsky AD, Harismendy O
    BMC Med Genomics. 2020 11 18; 13(1):173.; 
    PubMed
  5. Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective.
    Sharib J, Esserman L, Koay EJ, Maitra A, Shen Y, Kirkwood KS, Ozanne EM
    Surgery. 2020 10; 168(4):601-609.; 
    PubMed
  6. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.
    Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM
    Tomography. 2020 06; 6(2):216-222.; 
    PubMed
  7. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
    Piper ML, Wong J, Fahrner-Scott K, Ewing C, Alvarado M, Esserman LJ, Mukhtar RA
    NPJ Breast Cancer. 2019; 5:29.; 
    PubMed
  8. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium
    J Clin Oncol. 2020 04 01; 38(10):1059-1069.; 
    PubMed
  9. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.
    Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW
    NPJ Breast Cancer. 2018; 4:31.; 
    PubMed
  10. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K
    J Natl Cancer Inst. 2018 06 01; 110(6):560-567.; 
    PubMed
  11. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    DeMichele A, Yee D, Esserman L
    N Engl J Med. 2017 12 07; 377(23):2287-2289.; 
    PubMed
  12. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP
    Breast Cancer Res Treat. 2017 08; 165(1):161.; 
    PubMed
  13. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA, Athena Breast Health Network Investigators
    J Natl Cancer Inst. 2017 01; 109(5).; 
    PubMed
  14. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Berry D, Esserman L
    N Engl J Med. 2016 10 20; 375(16):1592-3.; 
    PubMed
  15. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
    Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, Anderson KS
    Proteomics Clin Appl. 2016 07; 10(7):720-31.; 
    PubMed
  16. Detection of ductal carcinoma in situ and subsequent interval cancers.
    Shieh Y, Eklund M, Esserman L
    BMJ. 2016 Feb 01; 352:i551.; 
    PubMed
  17. Rethinking the Standard for Ductal Carcinoma In Situ Treatment.
    Esserman L, Yau C
    JAMA Oncol. 2015 Oct; 1(7):881-3.; 
    PubMed
  18. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
    Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ
    Breast Cancer Res. 2015 May 29; 17:73.; 
    PubMed
  19. The impact of breast mass on outcomes of total skin-sparing mastectomy and immediate tissue expander-based breast reconstruction.
    Wang F, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H
    Plast Reconstr Surg. 2015 Mar; 135(3):672-679.; 
    PubMed
  20. Aggregate cost of mammography screening in the United States.
    Eklund M, O'Donoghue C, Esserman LJ
    Ann Intern Med. 2014 Aug 19; 161(4):305.; 
    PubMed
  21. Addressing overdiagnosis and overtreatment in cancer: a prescription for change.
    Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S
    Lancet Oncol. 2014 May; 15(6):e234-42.; 
    PubMed
  22. Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time?
    Esserman LJ, Alvarado MD, Howe RJ, Mohan AJ, Harrison B, Park C, O'Donoghue C, Ozanne EM
    Breast Cancer Res Treat. 2014 Apr; 144(2):371-8.; 
    PubMed
  23. Changing the terminology of cancer--reply.
    Esserman LJ, Thompson IM, Reid BJ
    JAMA. 2014 Jan 08; 311(2):203.; 
    PubMed
  24. Overdiagnosis and overtreatment in cancer: an opportunity for improvement.
    Esserman LJ, Thompson IM, Reid B
    JAMA. 2013 Aug 28; 310(8):797-8.; 
    PubMed
  25. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications.
    Piper M, Peled AW, Foster RD, Moore DH, Esserman LJ
    Ann Plast Surg. 2013 Apr; 70(4):435-7.; 
    PubMed
  26. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.
    Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L, I-SPY 1 TRIAL Investigators, Liotta LA, Becker KF, Petricoin EF
    Clin Cancer Res. 2012 Dec 01; 18(23):6426-35.; 
    PubMed
  27. Whole-genome analysis informs breast cancer response to aromatase inhibition.
    Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER
    Nature. 2012 Jun 10; 486(7403):353-60.; 
    PubMed
  28. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts.
    Warren Peled A, Foster RD, Stover AC, Itakura K, Ewing CA, Alvarado M, Hwang ES, Esserman LJ
    Ann Surg Oncol. 2012 Oct; 19(11):3402-9.; 
    PubMed
  29. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.
    Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES
    Breast. 2011 Dec; 20(6):529-33.; 
    PubMed
  30. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.
    Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES
    Clin Breast Cancer. 2011 Mar; 11(1):33-8.; 
    PubMed
  31. Lessons learned from genetic testing.
    Esserman L, Kaklamani V
    JAMA. 2010 Sep 01; 304(9):1011-2.; 
    PubMed
  32. Bacteriologic features of surgical site infections following breast surgery.
    Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman LJ, Chiu C, Hwang ES
    Am J Surg. 2009 Oct; 198(4):529-31.; 
    PubMed
  33. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients.
    Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L
    Int J Cancer. 2009 Mar 01; 124(5):1213-9.; 
    PubMed
  34. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
    Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM
    Radiology. 2008 Jul; 248(1):79-87.; 
    PubMed
  35. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R
    J Clin Oncol. 2007 Aug 20; 25(24):3680-7.; 
    PubMed
  36. Magnetic resonance imaging captures the biology of ductal carcinoma in situ.
    Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM
    J Clin Oncol. 2006 Oct 01; 24(28):4603-10.; 
    PubMed
  37. Genetic/familial high-risk assessment: breast and ovarian.
    Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN, National Comprehensive Cancer Network
    J Natl Compr Canc Netw. 2006 Feb; 4(2):156-76.; 
    PubMed
  38. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
    Petricoin EF, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA
    J Clin Oncol. 2005 May 20; 23(15):3614-21.; 
    PubMed
  39. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
    Ozanne EM, Esserman LJ
    Cancer Epidemiol Biomarkers Prev. 2004 Dec; 13(12):2043-52.; 
    PubMed
  40. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.
    Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM
    Ann Surg Oncol. 2003 May; 10(4):381-8.; 
    PubMed
  41. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G
    J Natl Cancer Inst. 2002 Jun 05; 94(11):844-51.; 
    PubMed
  42. Does timely assessment affect the anxiety associated with an abnormal mammogram result?
    Haas J, Kaplan C, McMillan A, Esserman LJ
    J Womens Health Gend Based Med. 2001 Jul-Aug; 10(6):599-605.; 
    PubMed
  43. Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer.
    Sepucha KR, Belkora JK, Tripathy D, Esserman LJ
    J Clin Oncol. 2000 Mar; 18(6):1230-8.; 
    PubMed
  44. Is routine frozen section assessment feasible in the practice environment of the 1990s?
    Esserman L, Weidner N
    Cancer J Sci Am. 1997 Sep-Oct; 3(5):266-7.; 
    PubMed
  45. Cost per anomaly: what does a diaphragmatic hernia cost?
    Metkus AP, Esserman L, Sola A, Harrison MR, Adzick NS
    J Pediatr Surg. 1995 Feb; 30(2):226-30.; 
    PubMed
  46. Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.
    Bui TBV, Wolf DM, Bruck MC, Moore K, Lien J, Choi SDW, Warhadpande S, Parizadeh A, Dillon D, Overmoyer B, Lynce F, Brown-Swigart L, Hirst GL, Yau C, I-SPY2 Investigators, Nijman IJ, Burgering BMT, Harris IS, Esserman LJ, van 't Veer LJ, Rosenbluth JM
    Cell Rep Med. 2026 Aug 06; 102973.; 
    PubMed
  47. Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
    Sun X, Ocampo AA, Hanna A, Taylor BC, Marshall JL, Steele JA, Axelrod ML, Wescott EC, Opalenik SR, DeMichele A, Esserman LJ, Liu MC, Nanda R, Wolf DM, Brown Swigart L, Hirst GL, van 't Veer LJ, Xu Y, Balko JM
    Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.; 
    PubMed
  48. Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
    Wildiers H, Adam V, O'Reilly S, Van Cauwenberge J, Arahmani A, Arteaga CL, Bedard PL, Bliss J, Boussis P, Brain E, Buyse M, Caballero C, Cameron D, Cardoso F, Carrasco E, Casas A, Chua B, Curigliano G, DeMichele A, Esserman L, Floris G, Goetz MP, Goulioti T, Haibe-Kains B, Hodgdon C, Ignatiadis M, Kok M, Lacombe D, Linderholm B, Loi S, Lord CJ, MacKenzie M, Maues J, Meheus L, Needham J, Neven P, Parsons H, Piccart M, Pusztai L, Razis E, Saji S, Schumacher-Wulf E, Sonke GS, Spanic T, Tannock IF, Tutt A, Urruticoechea A, van 't Veer L, Vaz-Luis I, Werutsky G, Yee D, Zaman K, Desmedt C
    JAMA Oncol. 2026 Feb 01; 12(2):200-207.; 
    PubMed
  49. Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.
    Abbasi AB, Liu KD, Russell DW, Files DC, Thomas KW, Youssef F, Gandotra S, Discacciati A, Lim N, Asare AL, Eklund M, Matthay M, Esserman LJ, I-SPY COVID Investigators
    Commun Med (Lond). 2025 Oct 29; 5(1):444.; 
    PubMed
  50. Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Hensley M, Lengfeld J, Stoesz S, Edwards M, Pass F, Hirst GL, Brown-Swigart L, van 't Veer L, Esserman LJ, Beckwith H, Yee D
    Front Oncol. 2025; 15:1605120.; 
    PubMed
  51. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Leon-Ferre RA, Dimitroff K, Yau C, Giridhar KV, Mukhtar R, Hirst G, Hylton N, Perlmutter J, DeMichele A, Yee D, van 't Veer L, Rugo H, Symmans WF, Goetz MP, Esserman L, Boughey JC
    Breast Cancer Res. 2025 Jun 23; 27(1):115.; 
    PubMed
  52. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
    Mukhtar RA, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, Boughey JC, Goetz MP, Hoskin T, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Provenzano E, Sammut SJ, Thomas JS, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, J van 't Veer L, Cameron D, Esserman LJ, Fraser Symmans W
    NPJ Breast Cancer. 2025 Feb 13; 11(1):14.; 
    PubMed
  53. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ
    Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.; 
    PubMed
  54. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
    Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Van't Veer LJ, Esserman L, Rugo HS
    Ann Oncol. 2025 02; 36(2):172-184.; 
    PubMed
  55. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    Switalla KM, Boughey JC, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait LM, Piltin M, Reyna CR, Matsen CB, Tuttle TM, Wallace AM, Arciero CA, Lee MC, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman LJ, Mukhtar RA
    Ann Surg Oncol. 2024 Oct; 31(11):7249-7259.; 
    PubMed
  56. Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
    Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, Farooq AV, Huppert LA, Rugo HS, Pohlmann PR, Lu J, Esserman LJ, Pasricha ND
    Curr Ophthalmol Rep. 2024 Jun; 12(2):13-22.; 
    PubMed
  57. Precision Oncology in Breast Cancer Surgery.
    Abbasi AB, Wu V, Lang JE, Esserman LJ
    Surg Oncol Clin N Am. 2024 04; 33(2):293-310.; 
    PubMed
  58. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
    Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA
    Res Sq. 2023 Jul 19.; 
    PubMed
  59. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    Mukhtar RA, Yau C, Esserman LJ
    JAMA Surg. 2023 06 01; 158(6):675.; 
    PubMed
  60. Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression.
    Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N
    bioRxiv. 2023 Mar 29.; 
    PubMed
  61. Informed consent process in the ISPY COVID trial is ethically acceptable.
    Files DC, Esserman L, Liu KD, Calfee CS
    Eur J Intern Med. 2023 01; 107:97.; 
    PubMed
  62. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.
    Files DC, Matthay MA, Calfee CS, Aggarwal NR, Asare AL, Beitler JR, Berger PA, Burnham EL, Cimino G, Coleman MH, Crippa A, Discacciati A, Gandotra S, Gibbs KW, Henderson PT, Ittner CAG, Jauregui A, Khan KT, Koff JL, Lang J, LaRose M, Levitt J, Lu R, McKeehan JD, Meyer NJ, Russell DW, Thomas KW, Eklund M, Esserman LJ, Liu KD, ISPY COVID Adaptive Platform Trial Network, undefined
    BMJ Open. 2022 06 06; 12(6):e060664.; 
    PubMed
  63. Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
    Lopes Cardozo JMN, Drukker CA, Rutgers EJT, Schmidt MK, Glas AM, Witteveen A, Cardoso F, Piccart M, Esserman LJ, Poncet C, van 't Veer LJ
    J Clin Oncol. 2022 04 20; 40(12):1335-1345.; 
    PubMed
  64. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
    Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA
    NPJ Breast Cancer. 2021 Oct 25; 7(1):139.; 
    PubMed
  65. Health screening needs independent regular re-evaluation.
    Ropers FG, Barratt A, Wilt TJ, Nicholls SG, Taylor-Phillips S, Kramer BS, Esserman LJ, Norris SL, Gibson LM, Harris RP, Carter SM, Jacklyn G, Jørgensen KJ
    BMJ. 2021 09 27; 374:n2049.; 
    PubMed
  66. Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
    Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ
    NPJ Breast Cancer. 2021 Jun 17; 7(1):78.; 
    PubMed
  67. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
    Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L
    NPJ Breast Cancer. 2021 Mar 25; 7(1):32.; 
    PubMed
  68. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
    Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ
    NPJ Breast Cancer. 2021 Jan 04; 7(1):2.; 
    PubMed
  69. The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
    Basu A, Philip EJ, Dewitt B, Hanmer J, Chattopadhyay A, Yau C, Melisko ME, Esserman LJ
    NPJ Breast Cancer. 2020; 6:52.; 
    PubMed
  70. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
    Abel MK, Brabham CE, Guo R, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Mukhtar RA
    PubMed
  71. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H
    Breast Cancer Res Treat. 2020 May; 181(1):23-29.; 
    PubMed
  72. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
    Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson AL, Van't Veer LJ, Esserman L, Park JW
    Clin Cancer Res. 2019 09 01; 25(17):5388-5397.; 
    PubMed
  73. The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.
    Eklund M, Broglio K, Yau C, Connor JT, Stover Fiscalini A, Esserman LJ
    JNCI Cancer Spectr. 2018 Oct; 2(4):pky067.; 
    PubMed
  74. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
    Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, Petricoin EF
    JCO Precis Oncol. 2018; 2.; 
    PubMed
  75. Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy.
    Chiu C, Aleshi P, Esserman LJ, Inglis-Arkell C, Yap E, Whitlock EL, Harbell MW
    BMC Anesthesiol. 2018 04 16; 18(1):41.; 
    PubMed
  76. Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME
    Breast Cancer Res Treat. 2018 01; 167(1):117-122.; 
    PubMed
  77. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N, Yau C, Li J, Esserman LJ, Rugo HS
    Breast Cancer Res Treat. 2017 Aug; 165(1):129-138.; 
    PubMed
  78. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
    Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM, ACRIN Trial team ISPY-1 Investigators
    J Magn Reson Imaging. 2017 07; 46(1):290-302.; 
    PubMed
  79. Laura Esserman and Ian Thompson Discuss Strategies for Screening and Treatment of Early-Stage Cancers, and How Clinicians Can Learn From Each Other's Experiences.
    Esserman LJ, Thompson IM
    Oncology (Williston Park). 2016 09 15; 30(9):770, 785-6.; 
    PubMed
  80. When the Gold Standard Loses Its Luster, Perhaps It Is Time to Change Nomenclature.
    Borowsky A, Esserman L
    Ann Intern Med. 2016 05 17; 164(10):694-5.; 
    PubMed
  81. Neoadjuvant as Future for Drug Development in Breast Cancer--Response.
    DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ, I-SPY2 Investigators
    Clin Cancer Res. 2016 Jan 01; 22(1):269.; 
    PubMed
  82. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
    Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF, Residual Disease Characterization Working Group of the Breast International Group-North American Bre
    Mod Pathol. 2015 Sep; 28(9):1185-201.; 
    PubMed
  83. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
    Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration
    Ann Oncol. 2015 Jul; 26(7):1280-91.; 
    PubMed
  84. Preoperative Breast Pain Predicts Persistent Breast Pain and Disability After Breast Cancer Surgery.
    Langford DJ, Schmidt B, Levine JD, Abrams G, Elboim C, Esserman L, Hamolsky D, Mastick J, Paul SM, Cooper B, Kober K, Dodd M, Dunn L, Aouizerat B, Miaskowski C
    J Pain Symptom Manage. 2015 Jun; 49(6):981-94.; 
    PubMed
  85. Impact of total skin-sparing mastectomy incision type on reconstructive complications following radiation therapy.
    Peled AW, Foster RD, Ligh C, Esserman LJ, Fowble B, Sbitany H
    Plast Reconstr Surg. 2014 Aug; 134(2):169-175.; 
    PubMed
  86. Oncoplastic mammoplasty as a strategy for reducing reconstructive complications associated with postmastectomy radiation therapy.
    Peled AW, Sbitany H, Foster RD, Esserman LJ
    Breast J. 2014 May-Jun; 20(3):302-7.; 
    PubMed
  87. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
    Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG, Northwestern Cancer Genetics Group
    Cancer. 2014 May 15; 120(10):1557-64.; 
    PubMed
  88. Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery.
    Alvarado MD, Conolly J, Park C, Sakata T, Mohan AJ, Harrison BL, Hayes M, Esserman LJ, Ozanne EM
    Breast Cancer Res Treat. 2014 Jan; 143(1):135-40.; 
    PubMed
  89. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer.
    Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM
    Ann Surg Oncol. 2013 Sep; 20(9):2873-80.; 
    PubMed
  90. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
    Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC
    Breast Cancer Res. 2013; 15(5):R103.; 
    PubMed
  91. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure.
    Peled AW, Foster RD, Esserman LJ, Park CC, Hwang ES, Fowble B
    Plast Reconstr Surg. 2012 Sep; 130(3):503-509.; 
    PubMed
  92. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators
    Radiology. 2012 Jun; 263(3):663-72.; 
    PubMed
  93. Targeting Molecular Aberrations in Breast Cancer: Is It about Time?
    Esserman L, Benz C, Demichele A
    Am Soc Clin Oncol Educ Book. 2012; 186-91.; 
    PubMed
  94. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ
    Breast Cancer Res Treat. 2011 Nov; 130(2):635-44.; 
    PubMed
  95. The Communication and Care Plan: a novel approach to patient-centered clinical information systems.
    Hogarth M, Hajopoulos K, Young M, Cowles N, Churin J, Hornthal B, Esserman L
    J Biomed Inform. 2010 Oct; 43(5 Suppl):S6-S8.; 
    PubMed
  96. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?
    Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, Esserman L, Fowble B
    Int J Radiat Oncol Biol Phys. 2011 May 01; 80(1):25-30.; 
    PubMed
  97. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
    Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ
    Clin Pharmacol Ther. 2009 Jul; 86(1):97-100.; 
    PubMed
  98. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
    Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J
    J Clin Oncol. 2009 Jan 10; 27(2):214-9.; 
    PubMed
  99. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
    Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP
    J Clin Oncol. 2008 Feb 10; 26(5):791-7.; 
    PubMed
  100. Ductal carcinoma in situ in BRCA mutation carriers.
    Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL
    J Clin Oncol. 2007 Feb 20; 25(6):642-7.; 
    PubMed
  101. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM
    Cancer Gene Ther. 2006 Nov; 13(11):1002-10.; 
    PubMed
  102. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI
    JAMA. 2005 Oct 19; 294(15):1925-33.; 
    PubMed
  103. Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans.
    Misell LM, Hwang ES, Au A, Esserman L, Hellerstein MK
    Breast Cancer Res Treat. 2005 Feb; 89(3):257-64.; 
    PubMed
  104. Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy.
    Esserman L
    Ann Surg Oncol. 2004 Jan; 11(1 Suppl):3S-8S.; 
    PubMed
  105. Efficacy of computerized infrared imaging analysis to evaluate mammographically suspicious lesions.
    Parisky YR, Sardi A, Hamm R, Hughes K, Esserman L, Rust S, Callahan K
    AJR Am J Roentgenol. 2003 Jan; 180(1):263-9.; 
    PubMed
  106. Magnetic resonance imaging for primary breast cancer management: current role and new applications.
    Esserman L, Wolverton D, Hylton N
    Endocr Relat Cancer. 2002 Jun; 9(2):141-53.; 
    PubMed
  107. Ductal growth is impeded in mammary glands of C-neu transgenic mice.
    Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G
    Oncogene. 2000 Dec 07; 19(52):5982-7.; 
    PubMed
  108. Prophylactic mastectomy in women with a high risk of breast cancer.
    Kuerer HM, Hwang ES, Esserman LJ
    N Engl J Med. 1999 Jun 10; 340(23):1838; author reply 1839.; 
    PubMed
  109. Barriers to care and treatment: the challenge of daily radiation therapy.
    Igoe S, Collins C, Hamolsky D, Esserman LJ
    Cancer Pract. 1996 Mar-Apr; 4(2):65-7.; 
    PubMed
  110. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R
    J Immunol. 1990 Aug 01; 145(3):1029-36.; 
    PubMed
  111. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
    Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ
    JAMA Oncol. 2026 Jul 30.; 
    PubMed
  112. Author Correction: Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.
    Abbasi AB, Liu KD, Russell DW, Files DC, Thomas KW, Youssef F, Gandotra S, Discacciati A, Lim N, Asare AL, Eklund M, Matthay M, Esserman LJ, I-SPY COVID Investigators
    Commun Med (Lond). 2026 Mar 24; 6(1).; 
    PubMed
  113. RISE UP for breast cancer 2024: conference highlights & takeaways.
    Glatt T, Leggat-Barr K, Seth N, Heditsian D, van 't Veer L, Pusztai L, Price E, Hylton N, Formenti S, Rugo H, Fejerman L, Toriola AT, Fabian C, De Censi A, Grossman D, Olopade O, Jackson A, Horton S, Rhoads K, Lange C, Borges V, Garner E, Garber J, Yee D, Esserman L
    Breast Cancer Res Treat. 2026 Jan 06; 215(2):53.; 
    PubMed
  114. Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.
    Petricoin EF, Wolf DM, Yau C, Wulfkuhle JD, Van't Veer L, Gallagher RI, Esserman LJ, Hirst GL, Brown-Swigart L, Yee D, I-SPY2 Trial Consortium
    Clin Cancer Res. 2025 Oct 15; 31(20):4361-4371.; 
    PubMed
  115. Pilot Study: Investigating the Local Breast Microbiome in Implant-based Breast Reconstruction Using 16S rRNA Sequencing.
    Barnes LL, Parmeshwar N, Campbell M, Esserman L, Piper M
    Plast Reconstr Surg Glob Open. 2025 Jul; 13(7):e6928.; 
    PubMed
  116. Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
    Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Tobin NP, Yau C, Benz CC, Esserman LJ, van 't Veer LJ, Nordenskjöld B, Stål O, Fornander T, Lindström LS
    J Natl Cancer Inst. 2025 May 01; 117(5):868-878.; 
    PubMed
  117. Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk.
    O'Keefe TJ, Alvarado MD, Esserman LJ
    JAMA Oncol. 2025 Feb 01; 11(2):185.; 
    PubMed
  118. A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
    Leggat-Barr K, Yee D, Duralde E, Hodge C, Borges V, Baxter M, Valdez J, Morgan T, Garber J, Esserman L
    Breast Cancer Res Treat. 2025 Jan; 209(1):1-14.; 
    PubMed
  119. Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.
    Fabian CJ, Mudaranthakam DP, Gajewski B, Young K, Winblad O, Khan SA, Garber JE, Esserman LJ, Yee LD, Nye L, Powers KR, Ranallo L, Kreutzjans AL, Pittman K, Altman C, Metheny T, Zelenchuk A, Komm BS, Kimler BF
    Contemp Clin Trials. 2024 11; 146:107697.; 
    PubMed
  120. Tumor microenvironmental determinants of high-risk DCIS progression.
    Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, Lee K, Nachmanson D, Officer A, Harismendy O, Stein J, Stein G, Evans M, Weaver D, Yau C, Hirst G, Campbell M, Esserman L
    Res Sq. 2024 May 09.; 
    PubMed
  121. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA
    NPJ Breast Cancer. 2024 Feb 26; 10(1):17.; 
    PubMed
  122. Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.
    Umashankar S, Basu A, Esserman L, Van't Veer L, Melisko ME
    Cancer Med. 2023 11; 12(22):20906-20917.; 
    PubMed
  123. A Truly Pro-Life Position Requires Access to Reproductive Health Care.
    Hull SC, Chou JC, Yee LM, Yee D, Esserman L
    J Womens Health (Larchmt). 2023 10; 32(10):1023-1026.; 
    PubMed
  124. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ
    Cancer Cell. 2023 06 12; 41(6):1091-1102.e4.; 
    PubMed
  125. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A
    Breast Cancer Res Treat. 2023 Apr; 198(2):383-390.; 
    PubMed
  126. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
    Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS
    J Clin Oncol. 2022 12 10; 40(35):4071-4082.; 
    PubMed
  127. Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer.
    Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, Esserman LJ, Hylton NM
    Tomography. 2022 04 22; 8(3):1208-1220.; 
    PubMed
  128. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF
    Lancet Oncol. 2022 01; 23(1):149-160.; 
    PubMed
  129. The use of neoadjuvant therapy to further personalize breast cancer treatment.
    Esserman LJ
    Clin Adv Hematol Oncol. 2021 Sep; 19(9):569-572.; 
    PubMed
  130. PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
    O'Grady N, Gibbs DL, Abdilleh K, Asare A, Asare S, Venters S, Brown-Swigart L, Hirst GL, Wolf D, Yau C, van 't Veer LJ, Esserman L, Basu A
    JAMIA Open. 2021 Apr; 4(2):ooab038.; 
    PubMed
  131. Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.
    Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ
    J Mammary Gland Biol Neoplasia. 2020 12; 25(4):417-432.; 
    PubMed
  132. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
    Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM
    NPJ Breast Cancer. 2020 Nov 27; 6(1):63.; 
    PubMed
  133. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer L
    NPJ Breast Cancer. 2020; 6:48.; 
    PubMed
  134. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
    Nguyen AA, Arasu VA, Strand F, Li W, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LJ, Newitt DC, Hylton NM
    Tomography. 2020 06; 6(2):101-110.; 
    PubMed
  135. We need more evidence to answer questions about screening.
    Esserman L
    Nature. 2020 03; 579(7800):S5.; 
    PubMed
  136. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM
    NPJ Breast Cancer. 2019; 5:12.; 
    PubMed
  137. Precision risk-based screening might maximize benefit and minimize harm.
    Esserman LJ, LaCroix AZ
    Nat Rev Clin Oncol. 2018 11; 15(11):661-662.; 
    PubMed
  138. The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia.
    Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS
    Future Oncol. 2018 Oct; 14(24):2461-2469.; 
    PubMed
  139. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
    Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC
    J Med Imaging (Bellingham). 2018 01; 5(1):011014.; 
    PubMed
  140. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L
    NPJ Breast Cancer. 2017; 3:31.; 
    PubMed
  141. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
    Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T
    JAMA. 2017 02 14; 317(6):606-614.; 
    PubMed
  142. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C
    Breast Cancer Res Treat. 2017 01; 161(1):41-50.; 
    PubMed
  143. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators
    N Engl J Med. 2016 Jul 07; 375(1):23-34.; 
    PubMed
  144. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN
    Breast Cancer Res Treat. 2016 Feb; 155(3):521-30.; 
    PubMed
  145. Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome.
    Johnson J, Esserman L, Ewing C, Alvarado M, Park C, Fowble B
    Ann Surg Oncol. 2016 Mar; 23(3):715-21.; 
    PubMed
  146. In Regard to Hepel and Wazer.
    Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M
    Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):953-954.; 
    PubMed
  147. Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy.
    Fowble B, Park C, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H, Hanlon A
    Int J Radiat Oncol Biol Phys. 2015 Jul 01; 92(3):634-41.; 
    PubMed
  148. Expression profiling of circulating tumor cells in metastatic breast cancer.
    Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW
    Breast Cancer Res Treat. 2015 Jan; 149(1):121-31.; 
    PubMed
  149. Immediate implant-based breast reconstruction following total skin-sparing mastectomy in women with a history of augmentation mammaplasty: assessing the safety profile.
    Sbitany H, Wang F, Saeed L, Alvarado M, Ewing CA, Esserman LJ, Foster RD
    Plast Reconstr Surg. 2014 Jul; 134(1):1-9.; 
    PubMed
  150. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).
    Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A, I-SPY1 Investigators
    Cancer Med. 2014 Jun; 3(3):693-701.; 
    PubMed
  151. Mammographic screening detects low-risk tumor biology breast cancers.
    Drukker CA, Schmidt MK, Rutgers EJ, Cardoso F, Kerlikowske K, Esserman LJ, van Leeuwen FE, Pijnappel RM, Slaets L, Bogaerts J, Van't Veer LJ
    Breast Cancer Res Treat. 2014 Feb; 144(1):103-11.; 
    PubMed
  152. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ
    PLoS One. 2013; 8(10):e79114.; 
    PubMed
  153. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.
    Flowers CI, O'Donoghue C, Moore D, Goss A, Kim D, Kim JH, Elias SG, Fridland J, Esserman LJ
    Breast Cancer Res Treat. 2013 Jun; 139(3):769-77.; 
    PubMed
  154. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
    Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L
    J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.; 
    PubMed
  155. Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer.
    Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L
    J Med Internet Res. 2012 Jul 11; 14(4):e97.; 
    PubMed
  156. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ
    Ann Surg Oncol. 2012 Nov; 19(12):3979-86.; 
    PubMed
  157. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
    Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR
    Lancet Oncol. 2011 Nov; 12(12):1162-8.; 
    PubMed
  158. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA
    rinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011 Jun 10; 29(17):2342-9.; 
    PubMed
  159. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience.
    Liu LC, Lang JE, Lu Y, Roe D, Hwang SE, Ewing CA, Esserman LJ, Morita E, Treseler P, Leong SP
    Cancer. 2011 Jan 15; 117(2):250-8.; 
    PubMed
  160. Application of screening principles to the reconstructed breast.
    Zakhireh J, Fowble B, Esserman LJ
    J Clin Oncol. 2010 Jan 01; 28(1):173-80.; 
    PubMed
  161. Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.
    Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ
    BMC Cancer. 2009 Apr 28; 9:127.; 
    PubMed
  162. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer?
    Liu LC, Lang JE, Jenkins T, Lu Y, Ewing CA, Hwang SE, Sokol S, Alvarado M, Esserman LJ, Morita E, Treseler P, Leong SP
    J Am Coll Surg. 2008 Dec; 207(6):853-8.; 
    PubMed
  163. Optimizing the total skin-sparing mastectomy.
    Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ
    Arch Surg. 2008 Jan; 143(1):38-45; discussion 45.; 
    PubMed
  164. Type and duration of exogenous hormone use affects breast cancer histology.
    Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES
    Ann Surg Oncol. 2007 Feb; 14(2):695-703.; 
    PubMed
  165. Mammographic, sonographic, and pathologic characteristics of Burkitt's lymphoma in a patient referred for diagnostic mammography.
    Esserman L, Sexton R, Yu QQ, Cabello-Inchausti B
    AJR Am J Roentgenol. 2006 Apr; 186(4):1029-32.; 
    PubMed
  166. Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients.
    Tan YY, Fan YG, Lu Y, Hwang S, Ewing C, Esserman L, Morita E, Treseler P, Leong SP
    Breast J. 2005 Jul-Aug; 11(4):248-53.; 
    PubMed
  167. Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital.
    Lee R, Beattie M, Crawford B, Mak J, Stewart N, Komaromy M, Esserman L, Shaw L, McLennan J, Strachowski L, Luce J, Ziegler J
    Genet Test. 2005; 9(4):306-12.; 
    PubMed
  168. Racial differences in mammographic breast density.
    del Carmen MG, Hughes KS, Halpern E, Rafferty E, Kopans D, Parisky YR, Sardi A, Esserman L, Rust S, Michaelson J
    Cancer. 2003 Aug 01; 98(3):590-6.; 
    PubMed
  169. Axillary metastasis from a malignant mullerian mixed tumor.
    Cura MA, Blanco M, Esserman L
    Breast J. 2002 Sep-Oct; 8(5):305-6.; 
    PubMed
  170. Improving the accuracy of mammography: volume and outcome relationships.
    Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, Gale A
    J Natl Cancer Inst. 2002 Mar 06; 94(5):369-75.; 
    PubMed
  171. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.
    Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM
    AJR Am J Roentgenol. 2000 Jul; 175(1):35-43.; 
    PubMed
  172. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.
    Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E
    J Clin Oncol. 1999 Jan; 17(1):110-9.; 
    PubMed
  173. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.
    Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD
    J Clin Oncol. 1996 Jan; 14(1):70-7.; 
    PubMed
  174. Myocardial performance and extracellular ionized calcium in a severely failing human heart.
    Ginsburg R, Esserman LJ, Bristow MR
    Ann Intern Med. 1983 May; 98(5 Pt 1):603-6.; 
    PubMed
  175. WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.
    Fiscalini A, Blum K, Fergus K, Hiatt RA, Naeim A, Kaster A, Scheuner MT, van 't Veer LJ, LaCroix AZ, Borowsky AD, Olopade OI, Park HL, Esserman J, Lancaster R, Heditsian D, Brain S, Lee V, Goodman DL, Ross KS, Wenger N, Parker BA, Madlensky L, Tice JA, Shieh Y, Ziv E, Arasu VA, Anton-Culver H, Kaplan CP, Rhoads KF, Badal K, Hogarth M, Petruse A, Soto IA, Leggat-Barr K, Goodman S, Atamer J, Ryu R, Adduci K, Matthews JB, Eklund M, Athena/WISDOM Network Collaborators and Advocate Partners, Sabacan LP, Esserman L
    NPJ Breast Cancer. 2026 May 24.; 
    PubMed
  176. Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial.
    Fergus KB, Ross KS, Scheuner MT, Blanco AM, Tice JA, Ziv E, Shieh Y, van 't Veer L, Olopade OI, Goodman DL, Tong BS, Harvey H, DeRosa D, Risty L, Silver E, Kaster A, Fiscalini AS, Blum K, Heise R, Sabacan L, Heditsian D, Brain S, Petruse A, Eklund M, Hiatt RA, Borowsky AD, Naeim A, Park HL, LaCroix AZ, Parker BA, Lancaster R, Esserman J, Wenger N, Arasu V, Anton-Culver H, Esserman LJ, Madlensky L
    JAMA Intern Med. 2026 03 01; 186(3):344-352.; 
    PubMed
  177. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.
    Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L
    Nat Commun. 2025 Dec 09; 16(1):9945.; 
    PubMed
  178. Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
    Howard FM, Dolezal J, Hieromnimon H, Venters S, Kochanny S, Li A, Borowsky A, Symmans WF, Wolf D, Brown-Swigart L, Sun A, Basu A, Hirst G, Nguyen LC, Asare A, Kanaparthi S, Khramtsova G, Blenman K, Shan NL, Fan C, Tolaney SM, Somlo G, Hudis CA, Sikov W, McCart L, Watson M, Carey L, Stover DG, Veer LV, Esserman LJ, Perou CM, Pusztai L, Olopade OI, Huo D, Nanda R, Pearson AT
    medRxiv. 2025 Aug 27.; 
    PubMed
  179. Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events.
    O'Keefe TJ, Yau C, Iaconetti E, Jeong E, Brabham C, Kim P, McGuire J, Griffin A, Wallace AM, Esserman LJ, Harismendy O, Hirst GL
    NPJ Breast Cancer. 2025 Jul 01; 11(1):63.; 
    PubMed
  180. MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer.
    Li W, Onishi N, Gibbs JE, Wilmes LJ, Le NN, Metanat P, Price ER, Joe BN, Kornak J, Yau C, Wolf DM, Magbanua MJM, LeStage B, van 't Veer LJ, DeMichele AM, Esserman LJ, Hylton NM
    Tomography. 2025 Feb 27; 11(3).; 
    PubMed
  181. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, Melisko M, Castillo P, Brown T, Heditsian D, Brain S, Simmons C, Hieken T, Ruddy KJ, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Asare A, Esserman L, Hershman DL, Basu A
    J Am Med Inform Assoc. 2025 01 01; 32(1):172-180.; 
    PubMed
  182. Screening Mammography for 40-Year-Old Women-Whose Decision?
    Kerlikowske K, Esserman L, Tice JA
    JAMA Intern Med. 2024 Nov 01; 184(11):1281-1282.; 
    PubMed
  183. Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence.
    Franklin JB, Marra C, Abebe KZ, Butte AJ, Cook DJ, Esserman L, Fleisher LA, Grossman CI, Kass NE, Krumholz HM, Rowan K, Abernethy AP, JAMA Summit on Clinical Trials Participants
    JAMA. 2024 08 05.; 
    PubMed
  184. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
    Ríos-Hoyo A, Cobain E, Huppert LA, Beitsch PD, Buchholz TA, Esserman L, van 't Veer LJ, Rugo HS, Pusztai L
    J Clin Oncol. 2024 08 01; 42(22):2632-2636.; 
    PubMed
  185. Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers.
    O'Keefe T, Yau C, Iaconetti E, Jeong E, Brabham C, Kim P, McGuire J, Griffin A, Wallace A, Esserman L, Harismendy O, Hirst G
    Res Sq. 2024 Jan 11.; 
    PubMed
  186. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
    Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, Mujir F, Esserman LJ, Olopade OI, Mukhtar RA
    Cancer Epidemiol Biomarkers Prev. 2023 08 01; 32(8):1107-1113.; 
    PubMed
  187. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
    Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M
    Front Oncol. 2023; 13:1192208.; 
    PubMed
  188. Guiding principles for the responsible development of artificial intelligence tools for healthcare.
    Badal K, Lee CM, Esserman LJ
    Commun Med (Lond). 2023 Apr 01; 3(1):47.; 
    PubMed
  189. Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A
    Nat Commun. 2022 Nov 21; 13(1):7140.; 
    PubMed
  190. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A
    Nat Commun. 2022 06 27; 13(1):3671.; 
    PubMed
  191. Survivorship after neoadjuvant chemotherapy - Authors' reply.
    Yau C, Osdoit M, Esserman LJ, Symmans WF
    Lancet Oncol. 2022 03; 23(3):e96.; 
    PubMed
  192. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
    Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A
    Nat Commun. 2021 11 05; 12(1):6427.; 
    PubMed
  193. Authors' Reply: To the Letter to the Editor by Groheux et al.
    Heath CL, Esserman LJ, Flavell RR, Melisko ME
    J Natl Compr Canc Netw. 2021 08 01; 19(8):xxx-xxxii.; 
    PubMed
  194. Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.
    Matthys MB, Dempsey AM, Melisko ME, Dreher N, Che ML, Van't Veer LJ, Esserman LJ, Basu A
    Cancer. 2021 07 01; 127(13):2342-2349.; 
    PubMed
  195. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
    Steenbruggen TG, Schaapveld M, Horlings HM, Sanders J, Hogewoning SJ, Lips EH, Vrancken Peeters MT, Kok NF, Wiersma T, Esserman L, van 't Veer LJ, Linn SC, Siesling S, Sonke GS
    JNCI Cancer Spectr. 2021 06; 5(3).; 
    PubMed
  196. Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
    Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, Hirst GL, Flavell RR, Chien AJ, Yee D, Isaacs CJ, Forero-Torres A, Esserman LJ, Melisko ME
    J Natl Compr Canc Netw. 2020 11; 18(11):1510-1517.; 
    PubMed
  197. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
    Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators
    J Breast Imaging. 2020 Aug; 2(4):352-360.; 
    PubMed
  198. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ
    JAMA Oncol. 2020 05 01; 6(5):676-684.; 
    PubMed
  199. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
    Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS
    JAMA Oncol. 2019 Sep 01; 5(9):1304-1309.; 
    PubMed
  200. Should we rename low risk cancers?
    Esserman LJ, Varma M
    BMJ. 2019 Jan 23; 364:k4699.; 
    PubMed
  201. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
    Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM, ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators
    Radiology. 2018 12; 289(3):618-627.; 
    PubMed
  202. Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers.
    Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR, Beswick A, Greenwood R, Ingram JC, Saunders C, Vaidya JS, Esserman L, Jatoi I, Brunt AM
    BJS Open. 2018 Aug; 2(4):162-174.; 
    PubMed
  203. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
    Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS
    JAMA Oncol. 2017 Nov 01; 3(11):1503-1510.; 
    PubMed
  204. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A
    Clin Breast Cancer. 2018 02; 18(1):e107-e113.; 
    PubMed
  205. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K
    J Clin Oncol. 2017 Apr 01; 35(10):1061-1069.; 
    PubMed
  206. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.
    Trusheim MR, Shrier AA, Antonijevic Z, Beckman RA, Campbell RK, Chen C, Flaherty KT, Loewy J, Lacombe D, Madhavan S, Selker HP, Esserman LJ
    Clin Pharmacol Ther. 2016 12; 100(6):713-729.; 
    PubMed
  207. Outcomes Following Oncoplastic Reduction Mammoplasty: A Systematic Review.
    Piper ML, Esserman LJ, Sbitany H, Peled AW
    Ann Plast Surg. 2016 May; 76 Suppl 3:S222-6.; 
    PubMed
  208. CLINICAL DECISIONS. Ductal Carcinoma In Situ.
    Merrill AL, Esserman L, Morrow M
    N Engl J Med. 2016 Jan 28; 374(4):390-2.; 
    PubMed
  209. Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
    Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ
    Ann Surg Oncol. 2015 Oct; 22(10):3338-45.; 
    PubMed
  210. Tumor Involvement of the Nipple in Total Skin-Sparing Mastectomy: Strategies for Management.
    Amara D, Peled AW, Wang F, Ewing CA, Alvarado M, Esserman LJ
    Ann Surg Oncol. 2015 Nov; 22(12):3803-8.; 
    PubMed
  211. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
    DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ
    Clin Cancer Res. 2015 Jul 01; 21(13):2911-5.; 
    PubMed
  212. Randomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction.
    Degnim AC, Hoskin TL, Brahmbhatt RD, Warren-Peled A, Loprinzi M, Pavey ES, Boughey JC, Hieken TJ, Jacobson S, Lemaine V, Jakub JW, Irwin C, Foster RD, Sbitany H, Saint-Cyr M, Duralde E, Ramaker S, Chin R, Sieg M, Wildeman M, Scow JS, Patel R, Ballman K, Baddour LM, Esserman LJ
    Ann Surg Oncol. 2014 Oct; 21(10):3240-8.; 
    PubMed
  213. Fifty years of age-based screening: time for a new risk-based screening approach.
    Kerlikowske K, O'Kane ME, Esserman LJ
    Evid Based Med. 2014 Oct; 19(5):183.; 
    PubMed
  214. Abstract 124: outcomes of total skin-sparing mastectomy and reconstruction in 924 breasts over 11 years.
    Wang F, Peled A, Foster R, Wang E, Ewing C, Alvarado M, Esserman L, Sbitany H
    Plast Reconstr Surg. 2014 Mar; 133(3 Suppl):139.; 
    PubMed
  215. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
    Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM
    J Magn Reson Imaging. 2014 Aug; 40(2):476-82.; 
    PubMed
  216. Total skin-sparing mastectomy in BRCA mutation carriers.
    Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ
    Ann Surg Oncol. 2014 Jan; 21(1):37-41.; 
    PubMed
  217. Developing safety criteria for introducing new agents into neoadjuvant trials.
    DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L
    Clin Cancer Res. 2013 Jun 01; 19(11):2817-23.; 
    PubMed
  218. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators
    Breast Cancer Res Treat. 2012 Nov; 136(1):35-43.; 
    PubMed
  219. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.
    Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M, BIG-NABCG collaboration
    Lancet Oncol. 2012 Jun; 13(6):e240-8.; 
    PubMed
  220. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
    Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A
    J Exp Med. 2012 Apr 09; 209(4):679-96.; 
    PubMed
  221. Leukocyte composition of human breast cancer.
    Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM
    Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2796-801.; 
    PubMed
  222. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ
    Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100.; 
    PubMed
  223. Expanding the reach of decision and communication aids in a breast care center: a quality improvement study.
    Belkora JK, Teng A, Volz S, Loth MK, Esserman LJ
    Patient Educ Couns. 2011 May; 83(2):234-9.; 
    PubMed
  224. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
    Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES
    BMC Cancer. 2009 Aug 18; 9:285.; 
    PubMed
  225. Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients.
    Garwood ER, Moore D, Ewing C, Hwang ES, Alvarado M, Foster RD, Esserman LJ
    Ann Surg. 2009 Jan; 249(1):26-32.; 
    PubMed
  226. Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates.
    Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L
    Lancet Oncol. 2008 Jul; 9(7):602-3.; 
    PubMed
  227. Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer.
    Adduci KM, Annis CE, DeVries S, Chew KL, Boutin J, Magrane G, Ljung BM, Waldman FM, Esserman LJ
    Cancer. 2007 Jun 25; 111(3):185-91.; 
    PubMed
  228. Breast cancer growth prevention by statins.
    Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC
    Cancer Res. 2006 Sep 01; 66(17):8707-14.; 
    PubMed
  229. Statins: health-promoting agents show promise for breast cancer prevention.
    Kumar AS, Esserman LJ
    Clin Breast Cancer. 2005 Dec; 6(5):455-9.; 
    PubMed
  230. Immune dysfunction and micrometastases in women with breast cancer.
    Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ
    Breast Cancer Res Treat. 2005 May; 91(2):163-71.; 
    PubMed
  231. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma.
    Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM
    Cancer. 2004 Jun 15; 100(12):2562-72.; 
    PubMed
  232. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?
    Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM
    Int Immunol. 2003 Apr; 15(4):467-75.; 
    PubMed
  233. Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians.
    Sepucha KR, Belkora JK, Mutchnick S, Esserman LJ
    J Clin Oncol. 2002 Jun 01; 20(11):2695-700.; 
    PubMed
  234. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
    Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N
    Ann Surg Oncol. 2001 Jul; 8(6):549-59.; 
    PubMed
  235. Management of ductal carcinoma in situ.
    Hwang ES, Esserman LJ
    Surg Clin North Am. 1999 Oct; 79(5):1007-30, viii.; 
    PubMed
  236. Hormone replacement therapy and breast cancer risk.
    Burke CC, Gullatte MM, Vigliani M, Ruggiero RJ, Esserman L, Crawford B
    Cancer Pract. 1997 Jul-Aug; 5(4):203-8.; 
    PubMed
  237. An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site.
    Takahashi S, Esserman L, Levy R
    Blood. 1991 Feb 15; 77(4):826-32.; 
    PubMed
  238. Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.
    Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerer HM, Lee MC, Moran MC, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA
    Ann Surg Oncol. 2026 Aug 03.; 
    PubMed
  239. A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.
    Switalla KM, Onishi N, Jones EF, Lawhn-Heath C, Ray KM, Hathi DK, Carmona-Bozo JC, Metanat P, Lopes AJ, Falade IO, Quirarte A, Gottipati S, Guo R, Molina-Vega J, Pullakhandam K, Bareng TJ, Watkins M, Chien AJ, Joe BN, Esserman LJ, Hylton N, Mukhtar RA
    Breast Cancer Res. 2026 Apr 11; 28(1).; 
    PubMed
  240. Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.
    Leggat-Barr K, Lewis T, Tice JA, Tsopurashvili E, Sayaman R, Warner P, Malvin K, Sabacan L, Perry-Solomon A, Theiner S, Acerbi I, Griffin A, McGuire J, Lee V, Borowsky AD, Wisdom Study and Athena Breast Health Network Investigators and Advocate Partners, Eklund M, Kaplan C, Hiatt RA, Fiscalini AS, Kerlikowske K, Shieh Y, Esserman L, Van't Veer L
    Breast Cancer Res Treat. 2026 Jan 28; 215(3):65.; 
    PubMed
  241. CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
    Wahner Hendrickson AE, Flatten KS, Weiskittel TM, Venkatachalam A, Strathman AR, Rossman OK, Meng XW, Schneider PA, Peterson KL, Correia C, Anderson OJ, Singh S, Couch FJ, Esserman LJ, Hylton NM, Onishi N, DeMichele AM, Chen J, Li H, Ingle JN, Goetz MP, Kaufmann SH
    NPJ Breast Cancer. 2025 Oct 24; 11(1):112.; 
    PubMed
  242. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC
    Ann Surg Oncol. 2025 Oct; 32(11):8243-8253.; 
    PubMed
  243. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L
    JCO Precis Oncol. 2025 Jun; 9:e2400776.; 
    PubMed
  244. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.
    Boughey JC, Yu H, Switalla K, Velle L, Lopes A, Wallace AM, Lancaster RB, Reyna CR, Tuttle TM, Jaskowiak N, Tchou J, Rao R, Lee MC, Naik AM, Golshan M, Arciero CA, Sauder CAM, Matsen CB, Yau C, Esserman L, Mukhtar RA, I-SPY2 Locoregional Working Group
    Ann Surg Oncol. 2025 May; 32(5):3278-3291.; 
    PubMed
  245. Relationship Between Perceived COVID-19 Risk and Change in Perceived Breast Cancer Risk: Prospective Observational Study.
    Baxter-King R, Naeim A, Huang TQ, Sepucha K, Stanton A, Rudkin A, Ryu R, Sabacan L, Vavreck L, Esserman L, Stover Fiscalini A, Wenger NS
    JMIR Cancer. 2024 Dec 02; 10:e47856.; 
    PubMed
  246. Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
    Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ
    NPJ Breast Cancer. 2024 Oct 14; 10(1):90.; 
    PubMed
  247. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
    Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, , ISPY2 Locoregional Working Group
    Ann Surg Oncol. 2024 Oct; 31(11):7420-7428.; 
    PubMed
  248. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
    Wang J, Suh JM, Woo BJ, Navickas A, Garcia K, Yin K, Fish L, Cavazos T, Hänisch B, Markett D, Yu S, Hirst G, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Goodarzi H
    bioRxiv. 2024 Mar 21.; 
    PubMed
  249. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF
    Cell Rep Med. 2023 12 19; 4(12):101312.; 
    PubMed
  250. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
    Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, Alvarado M, Ewing C, Mukhtar RA
    Ann Surg Oncol. 2023 Oct; 30(10):5999-6006.; 
    PubMed
  251. Development and testing of a polygenic risk score for breast cancer aggressiveness.
    Shieh Y, Roger J, Yau C, Wolf DM, Hirst GL, Swigart LB, Huntsman S, Hu D, Nierenberg JL, Middha P, Heise RS, Shi Y, Kachuri L, Zhu Q, Yao S, Ambrosone CB, Kwan ML, Caan BJ, Witte JS, Kushi LH, 't Veer LV, Esserman LJ, Ziv E
    NPJ Precis Oncol. 2023 May 15; 7(1):42.; 
    PubMed
  252. When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
    Esserman LJ, Ali H, McKenzie T
    J Clin Oncol. 2023 04 20; 41(12):2144-2150.; 
    PubMed
  253. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment.
    Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SE
    J Urol. 2023 01; 209(1):49-57.; 
    PubMed
  254. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ
    Cancer Cell. 2022 06 13; 40(6):609-623.e6.; 
    PubMed
  255. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
    Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Borowsky AD, Stein JL, Harismendy O
    NPJ Breast Cancer. 2022 Jan 13; 8(1):6.; 
    PubMed
  256. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ
    NPJ Breast Cancer. 2021 Oct 05; 7(1):131.; 
    PubMed
  257. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
    Khoury AL, Keane H, Varghese F, Hosseini A, Mukhtar R, Eder SE, Weinstein PR, Esserman LJ
    NPJ Breast Cancer. 2021 Sep 17; 7(1):123.; 
    PubMed
  258. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
    Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ
    Cancer Cell. 2021 07 12; 39(7):989-998.e5.; 
    PubMed
  259. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
    Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA
    NPJ Breast Cancer. 2021 Mar 05; 7(1):25.; 
    PubMed
  260. Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era.
    Kwon DH, Aggarwal RR, Esserman LJ, Belkora JK
    JCO Oncol Pract. 2021 04; 17(4):161-163.; 
    PubMed
  261. The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment.
    Hewitt K, Son J, Glencer A, Borowsky AD, Cooperberg MR, Esserman LJ
    Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2463-2474.; 
    PubMed
  262. Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M
    Nat Rev Clin Oncol. 2020 11; 17(11):687-705.; 
    PubMed
  263. Response to Carter et al.
    Eklund M, Broglio K, Yau C, Connor JT, Fiscalini AS, Esserman LJ
    JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa016.; 
    PubMed
  264. Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
    Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME
    Clin Breast Cancer. 2019 12; 19(6):443-449.e1.; 
    PubMed
  265. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators
    NPJ Breast Cancer. 2019; 5:2.; 
    PubMed
  266. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.
    Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y
    NPJ Breast Cancer. 2018; 4:24.; 
    PubMed
  267. Initial Clinical Experience With an Inducible Magnetic Seed System for Preoperative Breast Lesion Localization.
    Price ER, Khoury AL, Esserman LJ, Joe BN, Alvarado MD
    AJR Am J Roentgenol. 2018 Apr; 210(4):913-917.; 
    PubMed
  268. The WISDOM Study: breaking the deadlock in the breast cancer screening debate.
    Esserman LJ, WISDOM Study and Athena Investigators
    NPJ Breast Cancer. 2017; 3:34.; 
    PubMed
  269. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP
    Breast Cancer Res Treat. 2017 Aug; 165(1):151-159.; 
    PubMed
  270. Do Prolonged Prophylactic Antibiotics Reduce the Incidence of Surgical-Site Infections in Immediate Prosthetic Breast Reconstruction?
    Wang F, Chin R, Piper M, Esserman L, Sbitany H
    Plast Reconstr Surg. 2016 Dec; 138(6):1141-1149.; 
    PubMed
  271. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
    Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ
    Am J Transplant. 2017 01; 17(1):292-295.; 
    PubMed
  272. Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.
    Esserman L, Yau C
    JAMA Oncol. 2016 Mar; 2(3):395-6.; 
    PubMed
  273. The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction.
    Wang F, Peled AW, Chin R, Fowble B, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H
    Plast Reconstr Surg. 2016 Jan; 137(1):1-9.; 
    PubMed
  274. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
    Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ
    World J Clin Cases. 2015 Jul 16; 3(7):607-13.; 
    PubMed
  275. Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction.
    Piper M, Peled AW, Sbitany H, Foster RD, Esserman LJ, Price ER
    Ann Surg Oncol. 2016 Jan; 23(1):65-71.; 
    PubMed
  276. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.
    Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS
    Cancer Epidemiol Biomarkers Prev. 2015 Feb; 24(2):435-41.; 
    PubMed
  277. Moving beyond the breast cancer screening debate.
    Esserman L, O'Kane ME
    J Womens Health (Larchmt). 2014 Aug; 23(8):629-30.; 
    PubMed
  278. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction.
    Peled AW, Duralde E, Foster RD, Fiscalini AS, Esserman LJ, Hwang ES, Sbitany H
    Ann Plast Surg. 2014 May; 72 Suppl 1:S48-52.; 
    PubMed
  279. Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines.
    O'Donoghue C, Eklund M, Ozanne EM, Esserman LJ
    Ann Intern Med. 2014 Feb 04; 160(3):145.; 
    PubMed
  280. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M, TARGIT trialists' group
    Lancet. 2014 Feb 15; 383(9917):603-13.; 
    PubMed
  281. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ
    Ann Surg Oncol. 2013 Nov; 20(12):3823-30.; 
    PubMed
  282. Physician behaviors surrounding the implementation of decision and communication AIDS in a breast cancer clinic: a qualitative analysis of staff intern perceptions.
    Pass M, Volz S, Teng A, Esserman L, Belkora J
    J Cancer Educ. 2012 Dec; 27(4):764-9.; 
    PubMed
  283. Breast cancer screening: the questions answered.
    Autier P, Esserman LJ, Flowers CI, Houssami N
    Nat Rev Clin Oncol. 2012 10; 9(10):599-605.; 
    PubMed
  284. The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study.
    Peled AW, Foster RD, Garwood ER, Moore DH, Ewing CA, Alvarado M, Hwang ES, Esserman LJ
    Plast Reconstr Surg. 2012 Jun; 129(6):901e-908e.; 
    PubMed
  285. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators
    Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.; 
    PubMed
  286. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
    Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC
    Breast Cancer Res Treat. 2011 Sep; 129(2):607-16.; 
    PubMed
  287. Long-term prognostic role of functional limitations among women with breast cancer.
    Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, Moore DH, Slattery ML, Tammemagi M, Castillo A, Melisko M, Esserman L, Weltzien EK, Caan BJ
    J Natl Cancer Inst. 2010 Oct 06; 102(19):1468-77.; 
    PubMed
  288. Solving the overdiagnosis dilemma.
    Esserman L, Thompson I
    J Natl Cancer Inst. 2010 May 05; 102(9):582-3.; 
    PubMed
  289. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
    Olson JA, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ
    J Am Coll Surg. 2009 May; 208(5):906-14; discussion 915-6.; 
    PubMed
  290. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
    Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F
    BMC Cancer. 2008 Nov 21; 8:339.; 
    PubMed
  291. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
    Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA, Petricoin EF
    J Proteome Res. 2008 Apr; 7(4):1508-17.; 
    PubMed
  292. Analysis of molecular inversion probe performance for allele copy number determination.
    Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, Chen C, Heiser LM, Chin K, Esserman L, Gray JW, Spellman PT, Faham M
    Genome Biol. 2007; 8(11):R246.; 
    PubMed
  293. Clinical trials are required to prove the chemopreventive worth of statins.
    Kumar AS, Benz CC, Esserman LJ
    Arch Intern Med. 2006 May 22; 166(10):1143; author reply 1144.; 
    PubMed
  294. Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer.
    Tan YY, Wu CT, Fan YG, Hwang S, Ewing C, Lane K, Esserman L, Lu Y, Treseler P, Morita E, Leong SP
    Breast J. 2005 Sep-Oct; 11(5):338-43.; 
    PubMed
  295. Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease.
    Foster RD, Hansen SL, Esserman LJ, Hwang ES, Ewing C, Lane K, Anthony JP
    Arch Surg. 2005 Feb; 140(2):196-8; discussion 199-200.; 
    PubMed
  296. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.
    Hwang ES, Esserman L
    Ann Surg Oncol. 2004 Jan; 11(1 Suppl):37S-43S.; 
    PubMed
  297. Improving the quality of decision making in breast cancer: consultation planning template and consultation recording template.
    Sepucha KR, Belkora JK, Aviv C, Mutchnik S, Esserman LJ
    Oncol Nurs Forum. 2003 Jan-Feb; 30(1):99-106.; 
    PubMed
  298. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma.
    Foster RD, Esserman LJ, Anthony JP, Hwang ES, Do H
    Ann Surg Oncol. 2002 Jun; 9(5):462-6.; 
    PubMed
  299. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging.
    Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM
    AJR Am J Roentgenol. 2000 Dec; 175(6):1577-84.; 
    PubMed
  300. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
    Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ
    Cancer Immunol Immunother. 1999 Feb; 47(6):337-42.; 
    PubMed
  301. Should we recommend screening mammography for women aged 40 to 49?
    Esserman L, Kerlikowske K
    Oncology (Williston Park). 1996 Mar; 10(3):357-64; discussion: 370-6.; 
    PubMed
  302. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R
    Int Rev Immunol. 1989; 4(4):251-70.; 
    PubMed
  303. Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bank.
    Arasu VA, Gadgil T, Rothstein JH, Alexeeff SE, Achacoso NS, Bhattacharya A, Cord JB, Esserman LJ, Galbraith W, Gerstley LD, Head ST, Hylton NM, Kushi LH, Lee C, Leimpeter AD, Lewis DA, Liu V, Marafino BJ, Margolies LR, Navarro DA, Pu A, Sakoda LC, Shan J, Shieh Y, Sistig A, Smith Gueye CL, Veer LV, Villaseñor M, Westley M, Wisner DJ, Tice JA, Shen L, Habel LA, Sieh W
    J Natl Cancer Inst. 2026 Jun 23.; 
    PubMed
  304. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue.
    Goldhammer N, Bont M, Warhadpande S, Choi M, Cedano J, Greenwood H, Ye J, Schwartz CJ, Alvarado M, Ewing C, Goodwin K, Mukhtar RA, Wong J, Abe SE, Chandler J, Jackson J, Olopade OI, Campbell MJ, Lam A, Park C, Vertido A, van 't Veer LJ, Hylton N, Esserman LJ, Rosenbluth JM
    bioRxiv. 2026 Mar 04.; 
    PubMed
  305. Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.
    Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein DA, Sobrin L, Kim IK, Singh K, Chambers WA, Boyd WM, Silverstein J, Pohlmann PR, Lu J, Glencer AC, Huppert LA, Chien AJ, Rugo HS, Esserman LJ
    JAMA Ophthalmol. 2026 01 01; 144(1):62-68.; 
    PubMed
  306. Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial.
    Fergus KB, Heise RS, Madlensky L, Fiscalini A, Sabacan L, Theiner S, Kapoor S, Soto IA, Blanco A, Ross K, Goodman-Gruen D, Scheuner M, Hu D, Heditsian D, Brain S, Arasu VA, Kaster A, Chapa L, Olopade OI, Eklund M, Tice JA, Ziv E, van 't Veer L, Esserman LJ, Shieh Y, Athena/WISDOM Network Collaborators and Advocate Partners
    Genome Med. 2025 08 28; 17(1):97.; 
    PubMed
  307. Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer.
    Balko J, Sun X, Hanna A, Ocampo A, Taylor B, Marshall J, Steele J, Axelrod M, Wescott E, Opalenik S, DeMichele A, Esserman L, Liu M, Nanda R, Wolf D, Swigart LB, Hirst G, Van 't Veer L, Xu Y
    Res Sq. 2025 Jul 07.; 
    PubMed
  308. Impact of IVF Restriction on Patients With Cancer and Surgeons.
    Glencer AC, Esserman LJ
    JAMA Surg. 2025 Mar 01; 160(3):239-240.; 
    PubMed
  309. Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
    Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L
    Clin Cancer Res. 2025 Jan 17; 31(2):403-413.; 
    PubMed
  310. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
    Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Alvarado M, Julian BQ, Ewing C, Wong J, Rose J, Esserman L, Foster R, Mukhtar RA
    Am J Surg. 2025 Mar; 241:116073.; 
    PubMed
  311. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ
    Nat Med. 2024 Dec; 30(12):3728-3736.; 
    PubMed
  312. Reproductive rights in the United States: acquiescence is not a strategy.
    Esserman LJ, Yee D
    Nat Med. 2024 05; 30(5):1238-1240.; 
    PubMed
  313. Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.
    Alipanah-Lechner N, Hurst-Hopf J, Delucchi K, Swigart L, Willmore A, LaCombe B, Dewar R, Lane HC, Lallemand P, Liu KD, Esserman L, Matthay MA, Calfee CS, I-SPY COVID Consortium
    Crit Care. 2024 02 21; 28(1):56.; 
    PubMed
  314. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA
    Breast Cancer Res Treat. 2024 Jan; 203(2):245-256.; 
    PubMed
  315. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA
    Ann Surg Oncol. 2023 Oct; 30(11):6401-6410.; 
    PubMed
  316. Time to Surgery in Breast Cancer-Is Faster Always Better?
    Mukhtar RA, Esserman LJ
    JAMA Surg. 2023 05 01; 158(5):492-493.; 
    PubMed
  317. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ
    Cancer Res Commun. 2022 12; 2(12):1579-1589.; 
    PubMed
  318. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.
    Noordhoek I, Bastiaannet E, de Glas NA, Scheepens J, Esserman LJ, Wesseling J, Scholten AN, Schröder CP, Elias SG, Kroep JR, Portielje JEA, Kleijn M, Liefers GJ
    PubMed
  319. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    Mukhtar R, Symmans WF, Esserman LJ
    JAMA Oncol. 2022 04 01; 8(4):1.; 
    PubMed
  320. A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.
    Dreher N, Matthys M, Hadeler E, Shieh Y, Acerbi I, McAuley FM, Melisko M, Eklund M, Tice JA, Esserman LJ, Veer LJV
    Breast Cancer Res Treat. 2022 Feb; 191(3):623-629.; 
    PubMed
  321. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM
    Radiology. 2021 11; 301(2):295-308.; 
    PubMed
  322. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H, Johansson A, Nordenskjöld A, Iftimi A, Yau C, Perez-Tenorio G, Benz C, Nordenskjöld B, Stål O, Esserman LJ, Fornander T, Lindström LS
    JAMA Netw Open. 2021 06 01; 4(6):e2114904.; 
    PubMed
  323. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    Scheepens JCC, Veer LV', Esserman L, Belkora J, Mukhtar RA
    Breast. 2021 Apr; 56:61-69.; 
    PubMed
  324. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van 't Veer LJ
    Ann Oncol. 2021 02; 32(2):229-239.; 
    PubMed
  325. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA
    JAMA Oncol. 2020 09 01; 6(9):1355-1362.; 
    PubMed
  326. Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
    Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM
    Tomography. 2020 06; 6(2):77-85.; 
    PubMed
  327. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    Cao CX, Sharib JM, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS
    J Am Coll Surg. 2020 01; 230(1):53-63.e1.; 
    PubMed
  328. A response to "Personalised medicine and population health: breast and ovarian cancer".
    Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E
    Hum Genet. 2019 Mar; 138(3):287-289.; 
    PubMed
  329. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
    Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM, ACRIN Trial Team and I-SPY 2 TRIAL Investigators
    J Magn Reson Imaging. 2019 06; 49(6):1617-1628.; 
    PubMed
  330. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ, STO Trialists Group
    J Natl Cancer Inst. 2018 07 01; 110(7):726-733.; 
    PubMed
  331. Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
    Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM
    Oncotarget. 2018 Jan 30; 9(8):7832-7843.; 
    PubMed
  332. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
    van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS
    Breast Cancer Res Treat. 2017 Nov; 166(2):593-601.; 
    PubMed
  333. Precision surgery and avoiding over-treatment.
    Hosseini A, Khoury AL, Esserman LJ
    Eur J Surg Oncol. 2017 May; 43(5):938-943.; 
    PubMed
  334. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L
    Breast Cancer Res Treat. 2017 01; 161(1):17-28.; 
    PubMed
  335. When Less Is Better, but Physicians Are Afraid Not to Intervene.
    Esserman L
    JAMA Intern Med. 2016 07 01; 176(7):888-9.; 
    PubMed
  336. Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?
    Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L, Jatoi I, Brunt AM, MIAMI (Multiple Ipsilateral breast conserving surgery versus mastectomy) Trial Management Group
    Breast. 2016 Apr; 26:149-50.; 
    PubMed
  337. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
    Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators
    Radiology. 2016 Apr; 279(1):44-55.; 
    PubMed
  338. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    Mukhtar RA, Wong JM, Esserman LJ
    J Natl Compr Canc Netw. 2015 Jun; 13(6):737-43.; 
    PubMed
  339. Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer.
    Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M, TARGIT trialists' group
    Int J Radiat Oncol Biol Phys. 2015 Jul 01; 92(3):491-7.; 
    PubMed
  340. Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes.
    Sbitany H, Wang F, Peled AW, Lentz R, Alvarado M, Ewing CA, Esserman LJ, Fowble B, Foster RD
    Plast Reconstr Surg. 2014 Sep; 134(3):396-404.; 
    PubMed
  341. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis.
    Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM
    Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1464-83.; 
    PubMed
  342. Setting a research agenda for ductal carcinoma in situ that meets the current need for change.
    Esserman L, Alvarado M
    Ann Intern Med. 2014 Apr 01; 160(7):511-2.; 
    PubMed
  343. Development of a personalized decision aid for breast cancer risk reduction and management.
    Ozanne EM, Howe R, Omer Z, Esserman LJ
    BMC Med Inform Decis Mak. 2014 Jan 14; 14:4.; 
    PubMed
  344. Impact of ductal carcinoma in situ terminology on patient treatment preferences.
    Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM
    JAMA Intern Med. 2013 Oct 28; 173(19):1830-1.; 
    PubMed
  345. Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement.
    O'Donoghue C, Esserman L
    Br J Cancer. 2013 Jun 11; 108(11):2200-1.; 
    PubMed
  346. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
    Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE, American Society of Clinical Oncology
    J Clin Oncol. 2013 Mar 01; 31(7):961-5.; 
    PubMed
  347. Biology of breast cancer in Nigerian women: a pilot study.
    Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ
    Ann Afr Med. 2012 Jul-Sep; 11(3):169-75.; 
    PubMed
  348. Breast cancer recurrence is dictated by high-risk biology, not choice of surgery.
    Esserman LJ
    Oncology (Williston Park). 2012 May 15; 26(5).; 
    PubMed
  349. Impact of mammographic screening on the detection of good and poor prognosis breast cancers.
    Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ
    Breast Cancer Res Treat. 2011 Dec; 130(3):725-34.; 
    PubMed
  350. Characterizing the impact of 25 years of DCIS treatment.
    Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ
    Breast Cancer Res Treat. 2011 Aug; 129(1):165-73.; 
    PubMed
  351. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction.
    Warren Peled A, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, Alvarado M, Esserman LJ, Hwang ES
    Arch Surg. 2010 Sep; 145(9):880-5.; 
    PubMed
  352. Rethinking screening for breast cancer and prostate cancer.
    Esserman L, Shieh Y, Thompson I
    JAMA. 2009 Oct 21; 302(15):1685-92.; 
    PubMed
  353. The UCSC Cancer Genomics Browser.
    Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T
    Nat Methods. 2009 Apr; 6(4):239-40.; 
    PubMed
  354. Monitoring the implementation of Consultation Planning, Recording, and Summarizing in a breast care center.
    Belkora JK, Loth MK, Chen DF, Chen JY, Volz S, Esserman LJ
    Patient Educ Couns. 2008 Dec; 73(3):536-43.; 
    PubMed
  355. A role for biomarkers in the screening and diagnosis of breast cancer in younger women.
    Esserman LJ, Shieh Y, Park JW, Ozanne EM
    Expert Rev Mol Diagn. 2007 Sep; 7(5):533-44.; 
    PubMed
  356. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.
    Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ
    Am J Surg. 2006 Oct; 192(4):520-4.; 
    PubMed
  357. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations.
    Ozanne EM, Klemp JR, Esserman LJ
    Breast J. 2006 Mar-Apr; 12(2):103-13.; 
    PubMed
  358. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
    Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM
    AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81.; 
    PubMed
  359. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.
    Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES
    J Am Coll Surg. 2004 Dec; 199(6):856-62.; 
    PubMed
  360. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
    Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman LJ
    Cancer Res. 2003 May 15; 63(10):2347-50.; 
    PubMed
  361. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.
    Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman LJ, Peterlin BM
    Mol Cell Biol. 2002 Aug; 22(15):5616-25.; 
    PubMed
  362. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer.
    Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB
    J Natl Cancer Inst. 2001 Nov 07; 93(21):1624-32.; 
    PubMed
  363. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.
    Kuerer HM, Hwang ES, Anthony JP, Dudley RA, Crawford B, Aubry WM, Esserman LJ
    Ann Surg Oncol. 2000 Jun; 7(5):325-32.; 
    PubMed
  364. A multicenter randomized trial of DIAC for cyclical mastopathy.
    Ballagh SA, Stover TL, Maragos TG, Reynolds MD, Wolfley GD, Esserman LJ, Herbst JR, Kirkegaard LW, Teichman SL
    Prim Care Update Ob Gyns. 1998 Jul 01; 5(4):211.; 
    PubMed
  365. Potentially ineffective care. A new outcome to assess the limits of critical care.
    Esserman L, Belkora J, Lenert L
    JAMA. 1995 Nov 15; 274(19):1544-51.; 
    PubMed
  366. A novel method for emergency immobilization of the wrist during cross-country skiing.
    Goldman MP, Esserman LJ, Bausback KN, Camargo CA, Nagel DA
    Am J Sports Med. 1980 Jul-Aug; 8(4):285-6.; 
    PubMed
  367. Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, study.
    Files DC, Matthay MA, Chapple AG, Barragan AB, Mabrey L, Gibbs KW, Krall J, Aggarwal NR, Burnham EL, Liu KD, Meyer NJ, Nates JL, Youssef FA, Friedman E, Kett DH, Koff J, Russell DW, Calfee CS, Eklund M, Esserman LJ
    Lancet Respir Med. 2026 Jul; 14(7):601-608.; 
    PubMed
  368. Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.
    Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R
    Res Sq. 2026 Feb 11.; 
    PubMed
  369. FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ.
    Ye J, Goldhammer N, Vohra P, Warhadpande S, de Castro GC, Rodas CKM, Moasser MM, Ramalingam K, Abe SE, Alvarado M, Ewing C, Goodwin KM, Mukhtar RA, Wong JM, Esserman LJ, Balassanian R, Rosenbluth JM
    Cancer Cytopathol. 2025 11; 133(11):e70052.; 
    PubMed
  370. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
    Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R
    PubMed
  371. Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database.
    Kaur M, Quirarte A, Shui AM, Vertido A, Clelland E, Rothschild H, Esserman LJ, Ewing C, Mukhtar RA
    Breast Cancer Res Treat. 2025 Aug; 213(1):161-169.; 
    PubMed
  372. National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling.
    Badal K, Staib J, Tice JA, Kim MO, Eklund M, Wilson L, Dacosta Byfield S, Catlett K, Maffey L, Soonavala R, Shieh Y, Esserman LJ
    BMJ Open. 2025 Feb 17; 15(2):e089428.; 
    PubMed
  373. Anti-CD14 treatment in patients with severe COVID-19: Clinical and biological effects in a Phase 2 randomized open-label adaptive platform clinical trial.
    Mabrey FL, Martin TR, Calfee CS, Liu KD, LaCombe B, Brown-Swigart L, Discacciati A, Eklund M, Heckbert SR, Matthay MA, Esserman L, Wurfel MM
    CHEST Crit Care. 2025 Mar; 3(1).; 
    PubMed
  374. Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.
    McCune E, Sharma A, Johnson B, O'Meara T, Theiner S, Campos M, Heditsian D, Brain S, Gilbert JA, Esserman L, Campbell MJ
    mSystems. 2024 Nov 19; 9(11):e0123724.; 
    PubMed
  375. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A
    NPJ Breast Cancer. 2024 Aug 04; 10(1):71.; 
    PubMed
  376. RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    Omoleye OJ, Esserman LJ, Olopade OI
    J Natl Cancer Inst. 2024 04 05; 116(4):627-628.; 
    PubMed
  377. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.
    Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ
    Breast Cancer Res Treat. 2024 Apr; 204(3):509-520.; 
    PubMed
  378. Early Ascertainment of Breast Cancer Diagnoses Comparing Self-Reported Questionnaires and Electronic Health Record Data Warehouse: The WISDOM Study.
    Leggat-Barr K, Ryu R, Hogarth M, Stover-Fiscalini A, Veer LV', Park HL, Lewis T, Thompson C, Borowsky A, Hiatt RA, LaCroix A, Parker B, Madlensky L, Naeim A, Esserman L
    JCO Clin Cancer Inform. 2023 08; 7:e2300019.; 
    PubMed
  379. Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study.
    Arasu VA, Habel LA, Achacoso NS, Buist DSM, Cord JB, Esserman LJ, Hylton NM, Glymour MM, Kornak J, Kushi LH, Lewis DA, Liu VX, Lydon CM, Miglioretti DL, Navarro DA, Pu A, Shen L, Sieh W, Yoon HC, Lee C
    Radiology. 2023 06; 307(5):e222733.; 
    PubMed
  380. Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.
    Chitalia R, Miliotis M, Jahani N, Tastsoglou S, McDonald ES, Belenky V, Cohen EA, Newitt D, Van't Veer LJ, Esserman L, Hylton N, DeMichele A, Hatzigeorgiou A, Kontos D
    Commun Med (Lond). 2023 Mar 30; 3(1):46.; 
    PubMed
  381. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA
    JAMA Surg. 2022 11 01; 157(11):1034-1041.; 
    PubMed
  382. Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting.
    Chien AJ, Kyalwazi B, Esserman LJ
    Cell Rep Med. 2022 06 21; 3(6):100664.; 
    PubMed
  383. Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study.
    Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M
    JMIR Cancer. 2022 Feb 25; 8(1):e31756.; 
    PubMed
  384. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ
    JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.; 
    PubMed
  385. Advancing precision medicine for acute respiratory distress syndrome.
    Beitler JR, Thompson BT, Baron RM, Bastarache JA, Denlinger LC, Esserman L, Gong MN, LaVange LM, Lewis RJ, Marshall JC, Martin TR, McAuley DF, Meyer NJ, Moss M, Reineck LA, Rubin E, Schmidt EP, Standiford TJ, Ware LB, Wong HR, Aggarwal NR, Calfee CS
    Lancet Respir Med. 2022 01; 10(1):107-120.; 
    PubMed
  386. Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images.
    Liu G, Mitra D, Jones EF, Franc BL, Behr SC, Nguyen A, Bolouri MS, Wisner DJ, Joe BN, Esserman LJ, Hylton NM, Seo Y
    J Digit Imaging. 2021 06; 34(3):630-636.; 
    PubMed
  387. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
    Mukhtar RA, Brabham CE, Guo R, Abel MK, Wong J, Ewing C, Esserman LJ, Alvarado M
    Breast J. 2021 04; 27(4):406-408.; 
    PubMed
  388. Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M
    Nat Rev Clin Oncol. 2020 Nov; 17(11):716.; 
    PubMed
  389. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
    Abel MK, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Park C, Mukhtar RA
    Breast Cancer Res Treat. 2020 Oct; 183(3):661-667.; 
    PubMed
  390. Personalization of Treatment is the Way Forward in Care and Trials.
    Esserman LJ
    Clin Cancer Res. 2020 06 15; 26(12):2771-2773.; 
    PubMed
  391. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.
    Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ
    NPJ Breast Cancer. 2019; 5:17.; 
    PubMed
  392. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
    Ozanne EM, Howe R, Mallinson D, Esserman L, Van't Veer LJ, Kaplan CP
    J Genet Couns. 2019 06; 28(3):507-515.; 
    PubMed
  393. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators
    NPJ Breast Cancer. 2018; 4:26.; 
    PubMed
  394. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
    Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network
    AJR Am J Roentgenol. 2018 Jun; 210(6):1376-1385.; 
    PubMed
  395. The value of embedding: integrated palliative care for patients with metastatic breast cancer.
    Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H
    Breast Cancer Res Treat. 2018 02; 167(3):703-708.; 
    PubMed
  396. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY
    Breast Cancer Res Treat. 2017 Aug; 165(1):181-191.; 
    PubMed
  397. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM
    Clin Breast Cancer. 2017 06; 17(3):e155-e159.; 
    PubMed
  398. The I-SPY approach to drug development.
    Esserman L
    Clin Adv Hematol Oncol. 2016 Oct; 14(10):782-784.; 
    PubMed
  399. Population-based screening for cancer: hope and hype.
    Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ
    Nat Rev Clin Oncol. 2016 09; 13(9):550-65.; 
    PubMed
  400. Less Is More: The Evolving Surgical Approach to Breast Cancer.
    Esserman L, Gallant E, Alvarado M
    Am Soc Clin Oncol Educ Book. 2016; 35:e5-e10.; 
    PubMed
  401. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.
    Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP
    Breast Cancer Res Treat. 2015 Aug; 153(1):173-81.; 
    PubMed
  402. Coaching patients in the use of decision and communication aids: RE-AIM evaluation of a patient support program.
    Belkora J, Volz S, Loth M, Teng A, Zarin-Pass M, Moore D, Esserman L
    BMC Health Serv Res. 2015 May 28; 15:209.; 
    PubMed
  403. Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization.
    Warner JL, Maddux SE, Hughes KS, Krauss JC, Yu PP, Shulman LN, Mayer DK, Hogarth M, Shafarman M, Stover Fiscalini A, Esserman L, Alschuler L, Koromia GA, Gonzaga Z, Ambinder EP
    J Am Med Inform Assoc. 2015 May; 22(3):577-86.; 
    PubMed
  404. Haste makes waste, but lack of urgency is opportunity lost.
    Esserman L, Hayes M, Alvarado M
    Breast Cancer Res Treat. 2014 Aug; 147(1):223-4.; 
    PubMed
  405. Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).
    Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ
    Ann Surg Oncol. 2014 Sep; 21(9):2889-96.; 
    PubMed
  406. Making better doctors: a survey of premedical interns working as health coaches.
    Zarin-Pass M, Belkora J, Volz S, Esserman L
    J Cancer Educ. 2014 Mar; 29(1):167-74.; 
    PubMed
  407. Evolving paradigm for imaging, diagnosis, and management of DCIS.
    Wells CJ, O'Donoghue C, Ojeda-Fournier H, Retallack HE, Esserman LJ
    J Am Coll Radiol. 2013 Dec; 10(12):918-23.; 
    PubMed
  408. The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care.
    Elson SL, Hiatt RA, Anton-Culver H, Howell LP, Naeim A, Parker BA, Van't Veer LJ, Hogarth M, Pierce JP, Duwors RJ, Hajopoulos K, Esserman LJ, Athena Breast Health Network
    Breast Cancer Res Treat. 2013 Jul; 140(2):417-25.; 
    PubMed
  409. Reply: The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy.
    Peled AW, Esserman LJ
    Plast Reconstr Surg. 2013 Feb; 131(2):279e.; 
    PubMed
  410. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.
    Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ
    Breast Cancer Res Treat. 2012 Oct; 135(3):913-22.; 
    PubMed
  411. Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy.
    Chang EI, Peled AW, Foster RD, Lin C, Zeidler KR, Ewing CA, Alvarado M, Hwang ES, Esserman LJ
    Ann Surg. 2012 Jun; 255(6):1151-7.; 
    PubMed
  412. Overdiagnosis and overtreatment of breast cancer.
    Alvarado M, Ozanne E, Esserman L
    Am Soc Clin Oncol Educ Book. 2012; e40-5.; 
    PubMed
  413. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ, I-SPY TRIAL Investigators
    Breast Cancer Res Treat. 2012 Apr; 132(3):871-9.; 
    PubMed
  414. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
    Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC
    Breast Cancer Res. 2010; 12(5):R85.; 
    PubMed
  415. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
    Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M
    Lancet. 2010 Jul 10; 376(9735):91-102.; 
    PubMed
  416. A comparison of RNA amplification techniques at sub-nanogram input concentration.
    Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM
    BMC Genomics. 2009 Jul 20; 10:326.; 
    PubMed
  417. When informed, all women do not prefer breast conservation.
    Throckmorton AD, Esserman LJ
    J Clin Oncol. 2009 Feb 01; 27(4):484-6.; 
    PubMed
  418. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
    Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ
    Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1028-33.; 
    PubMed
  419. Pilot trial of a computerized decision aid for breast cancer prevention.
    Ozanne EM, Annis C, Adduci K, Showstack J, Esserman L
    Breast J. 2007 Mar-Apr; 13(2):147-54.; 
    PubMed
  420. Evaluation of a visit preparation intervention implemented in two rural, underserved counties of Northern California.
    Belkora J, Katapodi M, Moore D, Franklin L, Hopper K, Esserman L
    Patient Educ Couns. 2006 Dec; 64(1-3):350-9.; 
    PubMed
  421. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis.
    Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM
    Breast Cancer Res. 2005; 7(6):R1153-8.; 
    PubMed
  422. Integration of imaging in the management of breast cancer.
    Esserman L
    J Clin Oncol. 2005 Mar 10; 23(8):1601-2.; 
    PubMed
  423. Applying the neoadjuvant paradigm to ductal carcinoma in situ.
    Esserman L, Sepucha K, Ozanne E, Hwang ES
    Ann Surg Oncol. 2004 Jan; 11(1 Suppl):28S-36S.; 
    PubMed
  424. Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients.
    Wu CT, Morita ET, Treseler PA, Esserman LJ, Hwang ES, Kuerer HM, Santos CL, Leong SP
    Breast J. 2003 Mar-Apr; 9(2):86-90.; 
    PubMed
  425. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
    Campbell MJ, Wollish WS, Lobo M, Esserman LJ
    In Vitro Cell Dev Biol Anim. 2002 Jun; 38(6):326-33.; 
    PubMed
  426. The impact of alternative practices on the cost and quality of mammographic screening in the United States.
    Burnside E, Belkora J, Esserman L
    Clin Breast Cancer. 2001 Jul; 2(2):145-52.; 
    PubMed
  427. Biological therapies for breast carcinoma: concepts for improvement in survival.
    Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM
    Semin Oncol. 1999 Aug; 26(4 Suppl 12):28-40.; 
    PubMed
  428. Ultrasound tissue characterization of breast biopsy specimens: expanded study.
    Mortensen CL, Edmonds PD, Gorfu Y, Hill JR, Jensen JF, Schattner P, Shifrin LA, Valdes AD, Jeffrey SS, Esserman LJ
    Ultrason Imaging. 1996 Jul; 18(3):215-30.; 
    PubMed
  429. Follicular lymphoma: a model of lymphoid tumor progression in man.
    Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S
    Ann Oncol. 1991 Feb; 2 Suppl 2:115-22.; 
    PubMed
  430. ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.
    Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerrer HM, Lee MC, Moran MC, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Van't Veer LJ, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA
    Ann Surg Oncol. 2026 Jul 31.; 
    PubMed
  431. Screening for Breast Cancer-Reply.
    Esserman LJ, Olopade OI, Eklund M
    JAMA. 2026 Apr 06.; 
    PubMed
  432. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
    Wang J, Suh JM, Woo BJ, Navickas A, Garcia K, Yin K, Fish L, Cavazos T, Hänisch B, Markett D, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Goodarzi H
    Cell Rep Med. 2026 Feb 17; 7(2):102577.; 
    PubMed
  433. Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.
    Danielsson O, Dar H, Perez-Tenorio G, Nordenskjöld A, Yau C, Benz CC, Esserman LJ, Nordenskjöld B, Stål O, Fornander T, Hartman J, Tobin NP, Johansson A, Lindström LS
    Int J Cancer. 2026 Feb 15; 158(4):1106-1115.; 
    PubMed
  434. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
    Kaur M, Dimitroff K, Boughey JC, Esserman LJ, Yau C, Tchou J, Quirarte A, Lee MC, Howard-McNatt MM, Switalla K, Kuerer H, Sauder C, Postlewait LM, Arciero C, Rao R, Wallace A, Reyna C, Ahmed K, Gutnik L, Taunk N, Perlmutter J, DeMichele A, Yee D, Hylton NM, Symmans WF, Rugo HS, Shatsky RA, Isaacs C, Rudra S, Pohlmann P, Ewing C, Wong J, Alvarado M, Jaskowiak N, Prionas N, Golshan M, Piltin MA, Olopade OI, Mukhtar RA
    Ann Surg Oncol. 2025 Oct; 32(11):8211-8219.; 
    PubMed
  435. Pilot Study: A Prospective Placebo-control Trial Evaluating Topical Tranexamic Acid in Postmastectomy Breast Reconstruction.
    Parmeshwar N, Gozali A, Choi M, Knox JA, Bhaskerrao S, Lu Dugan C, Esserman L, Piper M
    Plast Reconstr Surg Glob Open. 2025 Jun; 13(6):e6863.; 
    PubMed
  436. Implantation of engineered adipocytes suppresses tumor progression in cancer models.
    Nguyen HP, An K, Ito Y, Kharbikar BN, Sheng R, Paredes B, Murray E, Pham K, Bruck M, Zhou X, Biellak C, Ushiki A, Nobuhara M, Fong SL, Bernards DA, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Klein JA, Valdiviez L, Fiehn O, Esserman L, Desai TA, Yee SW, Rosenbluth JM, Ahituv N
    Nat Biotechnol. 2025 Dec; 43(12):1979-1995.; 
    PubMed
  437. Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
    Li W, Le NN, Nadkarni R, Onishi N, Wilmes LJ, Gibbs JE, Price ER, Joe BN, Mukhtar RA, Gennatas ED, Kornak J, Magbanua MJM, Van't Veer LJ, LeStage B, Esserman LJ, Hylton NM
    Tomography. 2024 11 20; 10(11):1832-1845.; 
    PubMed
  438. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
    Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ
    Breast Cancer Res Treat. 2025 Jan; 209(1):147-159.; 
    PubMed
  439. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ
    Clin Cancer Res. 2024 Jun 03; 30(11):2444-2451.; 
    PubMed
  440. 18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
    Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, Jones EF, Ray KM
    Radiol Imaging Cancer. 2024 03; 6(2):e230082.; 
    PubMed
  441. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI
    JAMA Netw Open. 2023 12 01; 6(12):e2349646.; 
    PubMed
  442. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM, I-SPY 2 Imaging Working Group, I-SPY 2 Investigator Network
    Radiol Imaging Cancer. 2023 07; 5(4):e220126.; 
    PubMed
  443. Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.
    Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ
    Res Sq. 2023 May 10.; 
    PubMed
  444. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
    Barnes LL, Foster R, Mukhtar RA, Esserman LJ, Ewing C, Alvarado M, Wong J, Piper M
    Plast Reconstr Surg Glob Open. 2023 Jan; 11(1):e4767.; 
    PubMed
  445. Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
    Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, Esserman LJ, Van't Veer LJ, Hylton NM
    Cancers (Basel). 2022 Sep 13; 14(18).; 
    PubMed
  446. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium
    Ann Oncol. 2022 08; 33(8):814-823.; 
    PubMed
  447. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
    Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, Van 't Veer L, Esserman LJ, Mukhtar RA
    NPJ Breast Cancer. 2021 Dec 21; 7(1):156.; 
    PubMed
  448. Pre-Appointment Nurse Navigation: Patient-Centered Findings From a Survey of Patients With Breast Cancer.
    Wang T, Huilgol YS, Black J, D'Andrea C, James J, Northrop A, Belkora J, Esserman LJ
    Clin J Oncol Nurs. 2021 10 01; 25(5):E57-E62.; 
    PubMed
  449. The WISDOM study: a new approach to screening can and should be tested.
    Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M
    Breast Cancer Res Treat. 2021 Oct; 189(3):593-598.; 
    PubMed
  450. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA
    Am J Surg. 2022 04; 223(4):699-704.; 
    PubMed
  451. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF
    Ann Oncol. 2021 05; 32(5):642-651.; 
    PubMed
  452. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.
    Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF
    Sci Rep. 2020 12 14; 10(1):21930.; 
    PubMed
  453. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA
    Ann Surg Oncol. 2021 May; 28(5):2555-2560.; 
    PubMed
  454. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
    Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM
    Cancers (Basel). 2020 Jun 09; 12(6).; 
    PubMed
  455. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
    Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N
    J Clin Oncol. 2020 04 20; 38(12):1284-1292.; 
    PubMed
  456. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
    Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, I-SPY 2 Consortium, Esserman LJ, Hylton NM
    J Magn Reson Imaging. 2019 12; 50(6):1742-1753.; 
    PubMed
  457. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
    Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, Esserman L, Mukhtar R, Finlayson E
    JAMA Surg. 2018 12 01; 153(12):1090-1096.; 
    PubMed
  458. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    Mukhtar RA, Wong J, Piper M, Zhu Z, Fahrner-Scott K, Mamounas M, Sbitany H, Alvarado M, Foster R, Ewing C, Esserman L
    Ann Surg Oncol. 2018 Oct; 25(11):3165-3170.; 
    PubMed
  459. Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction.
    Peled AW, Sears M, Wang F, Foster RD, Alvarado M, Wong J, Ewing CA, Sbitany H, Esserman LJ, Fowble B
    Ann Plast Surg. 2018 Jan; 80(1):10-13.; 
    PubMed
  460. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
    Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L
    Breast Cancer Res. 2017 Sep 11; 19(1):107.; 
    PubMed
  461. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS
    JAMA Oncol. 2017 Mar 01; 3(3):313-319.; 
    PubMed
  462. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
    Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network
    Tomography. 2016 Dec; 2(4):378-387.; 
    PubMed
  463. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators
    N Engl J Med. 2016 Jul 07; 375(1):11-22.; 
    PubMed
  464. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
    Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM
    PLoS One. 2016; 11(2):e0142047.; 
    PubMed
  465. Tissue Expander Reconstruction After Total Skin-Sparing Mastectomy: Defining the Effects of Coverage Technique on Nipple/Areola Preservation.
    Sbitany H, Wang F, Peled AW, Alvarado M, Ewing CA, Esserman LJ, Foster RD
    Ann Plast Surg. 2016 Jan; 77(1):17-24.; 
    PubMed
  466. Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease?
    Peled AW, Wang F, Foster RD, Alvarado M, Ewing CA, Sbitany H, Esserman LJ
    Ann Surg Oncol. 2016 Jan; 23(1):87-91.; 
    PubMed
  467. Approaches to microvascular breast reconstruction after total skin-sparing mastectomy: a comparison of techniques.
    Raghavan S, Peled AW, Hansen SL, Esserman LJ, Sbitany H
    Ann Plast Surg. 2015 May; 74 Suppl 1:S46-51.; 
    PubMed
  468. SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer.
    Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME
    Cancer. 2015 Mar 15; 121(6):893-9.; 
    PubMed
  469. Total skin-sparing mastectomy and immediate breast reconstruction: an evolution of technique and assessment of outcomes.
    Wang F, Peled AW, Garwood E, Fiscalini AS, Sbitany H, Foster RD, Alvarado M, Ewing C, Hwang ES, Esserman LJ
    Ann Surg Oncol. 2014 Oct; 21(10):3223-30.; 
    PubMed
  470. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?
    Esserman LJ, DeMichele A
    Clin Cancer Res. 2014 Jul 15; 20(14):3632-6.; 
    PubMed
  471. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.
    Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM
    Transl Oncol. 2014 Feb; 7(1):94-100.; 
    PubMed
  472. Screening: biology dictates the fate of young women with breast cancer.
    Eklund M, Esserman LJ
    Nat Rev Clin Oncol. 2013 Dec; 10(12):673-5.; 
    PubMed
  473. Feasibility of Performing Total Skin-Sparing Mastectomy in Patients With Prior Circumareolar Mastopexy or Reduction Mammoplasty Incisions.
    Vaughn CJ, Peled AW, Esserman LJ, Foster RD
    Ann Plast Surg. 2013 Jun 19.; 
    PubMed
  474. Will early detection for breast cancer ever work?
    Esserman L, Ozanne E, van't Veer L
    Clin Chem. 2013 Jan; 59(1):190-3.; 
    PubMed
  475. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.
    Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M
    Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35.; 
    PubMed
  476. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N
    J Clin Oncol. 2012 Sep 10; 30(26):3242-9.; 
    PubMed
  477. Accelerating identification and regulatory approval of investigational cancer drugs.
    Esserman LJ, Woodcock J
    JAMA. 2011 Dec 21; 306(23):2608-9.; 
    PubMed
  478. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
    Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF
    JAMA. 2011 May 11; 305(18):1873-81.; 
    PubMed
  479. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
    Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ
    Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.; 
    PubMed
  480. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
    Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ
    Breast Cancer Res Treat. 2010 Jan; 119(1):137-44.; 
    PubMed
  481. Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer.
    Lang JE, Liu LC, Lu Y, Jenkins T, Hwang SE, Esserman LJ, Ewing CA, Alvarado M, Morita E, Treseler P, Leong SP
    Breast J. 2009 May-Jun; 15(3):242-6.; 
    PubMed
  482. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer.
    Zakhireh J, Gomez R, Esserman L
    Eur J Cancer. 2008 Dec; 44(18):2742-52.; 
    PubMed
  483. Training community resource center and clinic personnel to prompt patients in listing questions for doctors: follow-up interviews about barriers and facilitators to the implementation of consultation planning.
    Belkora J, Edlow B, Aviv C, Sepucha K, Esserman L
    Implement Sci. 2008 Jan 31; 3:6.; 
    PubMed
  484. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
    Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW
    Cancer Cell. 2006 Dec; 10(6):529-41.; 
    PubMed
  485. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.
    Kumar AS, Campbell M, Benz CC, Esserman LJ
    J Clin Oncol. 2006 May 01; 24(13):2127; author reply 2127-8.; 
    PubMed
  486. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
    Fan YG, Tan YY, Wu CT, Treseler P, Lu Y, Chan CW, Hwang S, Ewing C, Esserman L, Morita E, Leong SP
    Ann Surg Oncol. 2005 Sep; 12(9):705-11.; 
    PubMed
  487. Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment.
    Park C, Seid P, Morita E, Iwanaga K, Weinberg V, Quivey J, Hwang ES, Esserman LJ, Leong SP
    Breast J. 2005 Jan-Feb; 11(1):29-33.; 
    PubMed
  488. An XML message broker framework for exchange and integration of microarray data.
    Tjandra D, Wong S, Shen W, Pulliam B, Yu E, Esserman L
    Bioinformatics. 2003 Sep 22; 19(14):1844-5.; 
    PubMed
  489. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
    Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM
    AJR Am J Roentgenol. 2002 Nov; 179(5):1193-9.; 
    PubMed
  490. New approaches to the imaging, diagnosis, and biopsy of breast lesions.
    Esserman LJ
    Cancer J. 2002 May-Jun; 8 Suppl 1:S1-14.; 
    PubMed
  491. Integration of breast imaging into cancer management.
    Esserman LJ, Wolverton D, Hylton N
    Curr Oncol Rep. 2000 Nov; 2(6):572-81.; 
    PubMed
  492. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.
    Esserman L, Hylton N, George T, Weidner N
    Breast J. 1999 Jan; 5(1):13-21.; 
    PubMed
  493. Breast.
    Weidner N, Esserman LJ
    Pathology (Phila). 1996; 3(2):417-26.; 
    PubMed
  494. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
    Campbell MJ, Esserman L, Levy R
    J Immunol. 1988 Nov 01; 141(9):3227-33.; 
    PubMed
  495. Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study.
    Shieh Y, Heise RS, Madlensky L, Sabacan LP, Soto IA, Fiscalini AS, Ross K, Goodman D, Blanco A, Brain S, Heditsian DM, Moya J, Fergus KB, Olopade OI, Scheuner MT, Eklund M, Ziv E, Tice JA, van 't Veer L, Esserman LJ, Athena Breast Health Network and WISDOM Study Investigators and Advocate Partners
    JAMA Oncol. 2026 May 31.; 
    PubMed
  496. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
    Esserman LJ, Fiscalini AS, Naeim A, Van't Veer LJ, Kaster A, Scheuner MT, LaCroix AZ, Borowsky AD, Anton-Culver H, Olopade OI, Esserman J, Lancaster R, Madlensky L, Blanco AM, Ross KS, Goodman DL, Tong BS, Hogarth M, Heditsian D, Brain S, Lee V, Blum K, Kim MO, Sabacan LP, Fergus KB, Yau C, Park HL, Parker BA, Kaplan C, Rhoads KF, Eder S, Adduci K, Matthews JB, Wenger NS, Shieh Y, Hiatt RA, Ziv E, Tice JA, Eklund M
    JAMA. 2026 03 03; 335(9):763-774.; 
    PubMed
  497. WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and Design.
    Fiscalini A, Blum K, Fergus K, Hiatt RA, Naeim A, Kaster A, Scheuner MT, van 't Veer LJ, LaCroix AZ, Borowsky AD, Olopade OI, Park HL, Esserman J, Lancaster R, Heditsian D, Brain S, Lee V, Goodman DL, Ross KS, Wenger N, Parker BA, Madlensky L, Tice JA, Shieh Y, Ziv E, Arasu VA, Anton-Culver H, Kaplan CP, Rhoads KF, Badal K, Hogarth M, Petruse A, Soto IA, Leggat-Barr K, Goodman S, Atamer J, Ryu R, Adduci K, Matthews JB, Eklund M, Athena/WISDOM Network Collaborators and Advocate Partners, Sabacan LP, Esserman L
    Res Sq. 2025 Dec 15.; 
    PubMed
  498. Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies.
    Bui TBV, Wolf DM, Bruck MC, Moore K, Lien J, Choi SDW, Warhadpande S, Parizadeh A, Dillon D, Overmoyer B, Lynce F, I-SPY 2 Investigators, Nijman IJ, Burgering BMT, Harris IS, Esserman LJ, Veer LJV', Rosenbluth JM
    bioRxiv. 2025 Aug 28.; 
    PubMed
  499. Translating risk-based breast cancer screening to limited-resource settings.
    Badal K, Maniam A, Otis SU, Esserman LJ
    BMC Glob Public Health. 2025 Jul 03; 3(1):59.; 
    PubMed
  500. Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
    Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ
    JAMA Oncol. 2025 Mar 01; 11(3):288-292.; 
    PubMed
  501. Correction: A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
    Leggat-Barr K, Yee D, Duralde E, Hodge C, Borges V, Baxter M, Valdez J, Morgan T, Garber J, Esserman L
    Breast Cancer Res Treat. 2025 Jan; 209(1):207.; 
    PubMed
  502. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
    Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L
    Cell Rep Med. 2024 Nov 19; 5(11):101799.; 
    PubMed
  503. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ
    Nat Med. 2024 Dec; 30(12):3737-3747.; 
    PubMed
  504. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC, Sun X, Gonzalez-Ericsson P, Hanna A, Taylor BC, Sanchez V, Bronzini J, Opalenik SR, Sanders ME, Wulfkuhle J, Gallagher RI, Gomez H, Isaacs C, Bharti V, Wilson JT, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Hirst GL, Brown Swigart L, van 't Veer LJ, Esserman LJ, Petricoin EF, Pietenpol JA, Balko JM
    Cancer Res Commun. 2024 04 24; 4(4):1120-1134.; 
    PubMed
  505. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
    Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ
    Clin Cancer Res. 2024 02 16; 30(4):729-740.; 
    PubMed
  506. Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.
    Ho KKY, Kaiser UB, Chanson P, Gadelha M, Wass J, Nieman L, Little A, Aghi MK, Raetzman L, Post K, Raverot G, Borowsky AD, Erickson D, Castaño JP, Laws ER, Zatelli MC, Sisco J, Esserman L, Yuen KCJ, Reincke M, Melmed S
    Nat Rev Endocrinol. 2023 Nov; 19(11):671-678.; 
    PubMed
  507. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC, ISPY-2 Locoregional Working Group
    Ann Surg. 2023 09 01; 278(3):320-327.; 
    PubMed
  508. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, Wallace AM, I-SPY 2 Consortium, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ
    Breast Cancer Res Treat. 2023 Jun; 199(2):281-291.; 
    PubMed
  509. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ
    NPJ Breast Cancer. 2022 Dec 01; 8(1):128.; 
    PubMed
  510. Why It Is Time to Challenge Entrenched Beliefs About Breast Cancer Screening.
    Esserman LJ, Parker BA, LaCroix AZ
    J Womens Health (Larchmt). 2022 07; 31(7):903-904.; 
    PubMed
  511. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
    Johansson A, Yu NY, Iftimi A, Tobin NP, van 't Veer L, Nordenskjöld B, Benz CC, Fornander T, Perez-Tenorio G, Stål O, Esserman LJ, Yau C, Lindström LS
    Int J Cancer. 2022 06 15; 150(12):2072-2082.; 
    PubMed
  512. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
    Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM
    Nat Commun. 2021 11 05; 12(1):6428.; 
    PubMed